

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)


PCT

(10) International Publication Number
WO 02/26941 A2

- (51) International Patent Classification⁷: C12N 5/08, TROPEPE, Vincent [CA/US]; 56 Charlesgate East, Apt. 132, Boston, MA 02215 (US).
A61P 25/28, A61K 48/00, C12N 5/06
- (21) International Application Number: PCT/CA01/01383 (74) Agent: BERESKIN & PARR; 40 King Street West, Box 401, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).
- (22) International Filing Date: 28 September 2001 (28.09.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/236,394 29 September 2000 (29.09.2000) US
- (71) Applicants and (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
- (72) Inventors: VAN DER KOOY, Derek [CA/CA]; 144 MacPherson Avenue, Toronto, Ontario M5R 1W8 (CA).

[Continued on next page]

(54) Title: PRIMITIVE NEURAL STEM CELLS AND METHOD FOR DIFFERENTIATION OF STEM CELLS TO NEURAL CELLS



(57) Abstract: Described are a novel cell type in the neural lineage, and method of producing the same based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. The novel cell type of neural lineage and cells derived therefrom have a number of applications including applications regarding tissue engineering, transplantation and gene therapy and drug discovery. Also described are suggested uses of the method and cell type including isolating genes that positively and negatively regulate the transition from an ES cell to a neural cell and generally for studying ES cell models of mammalian neural development.

WO 02/26941 A2



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

Title: Primitive Neural Stem Cells And Method For Differentiation Of Stem Cells To Neural Cells

RELATED APPLICATIONS

- 5 This application claims priority from United States Provisional Patent Application No. 60/236,394 filed September 29, 2000, entitled "Primitive Neural Stem Cells And Method For Differentiation Of Stem Cells To Neural Cells".

FIELD OF THE INVENTION

- 10 This invention is in the field of cellular differentiation, more particularly to differentiation of stem cells to neural cells, to novel primitive neural cells and to methods of differentiation and uses thereof.

BACKGROUND OF THE INVENTION

- 15 Neural stem cells have a fundamental role in generating cellular diversity in the developing mammalian nervous system. However, there is very little known about how neural stem cells are formed initially in embryogenesis. Evidence from studies primarily in *Xenopus* suggest that the acquisition of a neural fate in ectoderm cells is actively repressed and that escaping the repressive signal is the predominant
20 mechanism by which cells reveal their default neural identity (Hemmati-Brivanlou and Melton, 1997). However, it is uncertain whether default neural specification occurs in mammalian development, and if so whether the process of default neural fate specification is homologous among vertebrate species.

- 25 During mouse gastrulation cells derived from the embryonic ectoderm are organized into either neural or epidermal primordia. The concept of vertebrate neural induction, borne out of studies in amphibian embryology, was proposed to account for the segregation of these two vertebrate ectodermal lineages (Spemann and Mangold, 1924; Waddington and Schnidt, 1933; Oppenheimer, 1936; Beddington,
30 1994). It was postulated that the nascent embryonic ectoderm received a positive inducing signal from the dorsal organizer tissue during gastrulation, which caused the ectodermal cells to adopt a neural fate in

- 2 -

a restricted manner. In the absence of this signal, ectodermal cells were presumed to differentiate into epidermis, independent of any cellular communication.

Results from in vitro experiments of isolated ectodermal (animal cap) cells derived from amphibian gastrula supported a different model for neural fate specification. Prolonged low-density dissociation of ectodermal cells, in the absence of organizer tissue, resulted in most of the cells expressing neural markers or forming neural structures upon reaggregation (Godsave and Slack, 1989; Grunz and Tacke, 1989; Sato and Sargent, 1989). Furthermore, ectodermal explants (undissociated cells) expressing a dominant-negative receptor for activin (a member of the TGF β superfamily of growth factors) were shown to become neural when cultured in vitro (Hemmati-Brivanlou and Melton, 1994). In studies aimed at identifying the nature of the organizer signals, molecules isolated from mesendodermal tissue, such as noggin and chordin, were found to be sufficient for inducing a second neural axis in analogous ectopic experiments performed in *Xenopus* (Smith et al., 1993; Sasai et al., 1995). However, the biochemical mechanism by which organizer signals promoted neural differentiation of ectodermal cells was not entirely consistent with a positive induction model for neural fate determination. Noggin and chordin were shown to act by binding extracellularly to bone morphogenetic proteins (BMPs), members of the TGF β superfamily of molecules that strongly inhibit neural differentiation (Hemmati-Brivanlou and Melton, 1994). Thus, in a restricted manner, noggin and chordin prevent the binding of BMPs to their cognate receptors expressed on the surface of ectodermal cells (Piccolo et al., 1996; Zimmerman et al., 1996). In fact, BMP4 was shown to act as a positive signal for epidermal fate determination in the *Xenopus* ectoderm (Wilson and Hemmati-Brivanlou, 1995). These findings from amphibian experiments were consistent with the notion that the establishment of neural identity from the uncommitted ectoderm occurs by default (i.e. a state achieved autonomously after the removal of the inhibitory signals) in the absence of neural-inducing factors

- 3 -

emanating from the organizer.

Embryonic stem (ES) cells are precursors to all embryonic lineages. ES cells are derived from the inner cell mass (ICM) of the pre-implantation mouse embryo (Evans and Kaufman, 1981; Martin, 1981) and can be sustained in an undifferentiated state in vitro while maintaining ICM characteristics. In prior studies of the neuronal differentiation of embryonic stem (ES) cells each experiment was preceded by embryoid body (EB) formation in the presence of serum. As a result, the derivation of neural cells was accomplished indirectly and under conditions where many culture media parameters are unknown.

The present inventors described evidence of a default model of neural cell fate in Tropepe et al, (1999, Neuroscience Abstracts, vol. 25, p527), wherein ES cells were cultured in serum-free, low density conditions wherein a small percentage (less than 1%) of embryonic stem cells proliferate in the presence of LIF to form sphere colonies that express neuroepithelial marker and that these cells could further differentiate to a different neural stage that is FGF2 but not LIF dependent. However the methodology and characteristics disclosed in the abstract did not provide enabling details of the required density and other culture conditions of the method, or details of the characteristics of the resulting cells developed under such conditions.

It is desirable to have a method for differentiating ES cells toward neural cells more directly. Furthermore, it is desirable to have a model system with known constituents and well defined end products for the differentiation of neural cells from ES cells. Such a system would be useful in analyzing the role of single genes in the regulation of neural development, and for the development and testing of drugs for the treatment of developmental and cerebral neural anomalies and neuropathies.

SUMMARY OF THE INVENTION

The present invention concerns a novel primitive neural stem cell and associated methods for differentiating embryonic stem cells

- 4 -

toward neural cells under completely defined media conditions, and methods of use of the new stem cell and methods of differentiation. The present inventors have made useful developments to optimize the default model of neural cell fate, the cells obtained therefrom and the
5 uses and methods therefor.

In accordance with the present invention, it has surprisingly been discovered that in low-density cell culture assays, in the absence of serum-derived or feeder cell-derived factors and in the absence of embryoid body (EB) formation, ES cells directly differentiate into neural
10 cells. The transition from ES cell to neural cell can be enhanced by the inhibition of TGF β -related signaling, in a manner that is consistent with a default model of neural fate specification, but one which is distinct from *Xenopus* default neuralization. Furthermore, the present invention describes a previously unidentified primitive neural stem cell stage in
15 the neural lineage, which defines the transition between ES cell and neural stem cell.

Accordingly, in its broad aspect the present invention provides a novel primitive neural stem cell; this cell being characterized in that it defines the transition between ES cell and neural stem cell.

20 According to one embodiment of the present invention there is provided one or more cells expressing one or more neural precursor cell marker(s), preferably nestin, and one or more neural-specific mRNA molecule(s), preferably Emx2 and/or HoxB1, and having multilineage potential.

25 In another broad aspect, the present invention provides a method for differentiating one or more pluripotent embryonic stem (ES) cell(s) toward neural cells. According to one embodiment the method comprises: a) obtaining ES cells and serum-free media; b) culturing the ES cells at low density in the serum-free media, preferably the ES
30 cells are cultured at a density of greater than zero and less than about 50 cells/ μ l, more preferred between about 1 cell/ μ l and about 50 cells/ μ l, even more preferably the ES cells are cultured at a density of 20 or fewer cells/ μ l; and most preferably at a density of 10 or fewer cells/ μ l

- 5 -

(but greater than 0 cells/ μ l) and c) allowing said ES cell(s) to differentiate toward the neural cell(s).

According to another embodiment the present invention provides a method for differentiating one or more pluripotent embryonic stem (ES) cell(s) toward neural cells the method comprising: a) obtaining
5 ES cells and serum-free media wherein a cytokine is added to the media, preferably the cytokine is leukemia inhibitory factor (LIF); b) culturing the ES cells at low density in the serum-free media, preferably the ES cells are cultured at a density greater than zero and less than
10 about 50 cells/ μ l, more preferred between about 1 cell/ μ l and about 50 cells/ μ l, even more preferably the ES cells are cultured at a density of 20 or fewer cells/ μ l; and most preferably at a density of 10 or fewer cells/ μ l (but greater than 0 cells/ μ l); and c) allowing said ES cell(s) to differentiate toward the neural cell(s).

15 According to yet another embodiment the present invention provides a method for differentiating one or more pluripotent embryonic stem (ES) cell(s) toward neural cell(s) the method comprising: (a) obtaining ES cells and serum-free media wherein one or more cytokines is/are added to the media, preferably the cytokine is leukemia
20 inhibitory factor (LIF), and one or more growth factors is/are added to the media, preferably the growth factor is selected from the members of the fibroblast growth factor (FGF) family of growth factors, more preferably the growth factor is FGF2; (b) culturing the ES cells at low density in the serum-free media, preferably the ES cells are cultured at a density
25 preferably the ES cells are cultured at a density between about 1 cell/ μ l and about 50 cells/ μ l, more preferably the ES cells are cultured at a density of 20 cell/ μ l ; and (c) allowing said ES cell(s) to differentiate toward the neural cell(s).

In another embodiment according to the present invention there
30 is provided a method for differentiating one or more pluripotent embryonic stem (ES) cell(s) toward neural cell(s) the method comprising: (a) obtaining ES cells and serum-free media, preferably wherein one or more cytokines is/are added to the media, preferably the

cytokine is leukemia inhibitory factor (LIF), preferably one or more growth factors is/are also added to the media, preferably the growth factor is selected from the members of the fibroblast growth factor (FGF) family of growth factors, more preferably the growth factor is FGF2

5 ; (b) culturing the ES cells at low density in the serum-free media, preferably the ES cells are cultured at a density greater than zero and less than about 50 cells/ μ l, more preferred between about 1 cell/ μ l and about 50 cells/ μ l, even more preferably the ES cells are cultured at a density of 20 or fewer cells/ μ l; and most preferably at a density of 10 or

10 fewer cells/ μ l (but greater than 0 cells/ μ l); and (c) allowing said ES cell(s) to differentiate toward the neural cell(s).

In one embodiment of the methods of the invention an inhibitor of TGF- β -related signaling is administered to the media, preferably the inhibitor is the protein Noggin. In yet another embodiment of the

15 method of the invention the inhibitor is selected from among the Cerberus family of proteins.

In another aspect, the present invention provides a method for producing secondary neural stem cell colonies. According to one embodiment, the method comprises: (a) culturing ES cells in low cell

20 density completely defined serum-free media for a sufficient time and under appropriate conditions to allow differentiation of the ES cells; (b) dissociating and subcloning primary neural cell colonies generated from the said ES cells; and (c) administering a growth factor to the dissociated neural cells, preferably the growth factor is selected from

25 among the members of the fibroblast growth factor (FGF) family of growth factors, more preferably the growth factor is FGF2.

According to another embodiment the present invention provides a method for producing secondary neural stem cell colonies the method comprising: (a) culturing ES cells in low cell density completely defined

30 serum-free media for a sufficient time and under appropriate conditions to allow differentiation of the ES cells; (b) dissociating and subcloning primary neural cell colonies generated from the said ES cells; and (c) administering a growth factor to the dissociated neural cells, preferably

- 7 -

the growth factor is selected from among the members of the fibroblast growth factor (FGF) family of growth factors, more preferably the growth factor is FGF2, and a cytokine is administered to the dissociated neural cells, preferably the cytokine is LIF or B27.

5 In yet another broad aspect, the present invention provides a method for analyzing the role of genes in the regulation of neural fate specification through analysis of genetic changes which occur during the neural differentiation of the metthods and cells of the present invention. In one embodiment this can be done by detecting the
10 presence or absence of gene expression through convention techniques such as RT-PCR or methods of protein expression analysis.

In another embodiment, the invention the novel cells and methods for forming them of the invention can be used in an assay for designing and/or screening for modulators or differentiation factors of
15 cell differentiation, preferably neural cell differentiation and development. Thus the cells and methods of the invention can be used in drug screening and discovery assays, and in tissue engineering. Such methods could involve the culturing of ES cells in serum free media, under low density conditions in the presence of such
20 modulators or differentiation factors and in the presence or absence of cytokines, such as LIF and/or growth factors such as FGF-2. The effect on differentiation of the ES cells can then be montioered. In another embodiment, the novel primitive neural cells of the invention can be cultured in the presence of the modulator or differentiating factor and in
25 the presence of absence of growth factors such as FGF2. The effect on differentiation can then be monitored.

Once the modulators or differentiating factors are determined, for instance the differentiation factor to develop a particular cell type from the primitive neural cell type, such cells can be used to specifically
30 generate such cells.

In another embodiment, novel cells of the invention and cells produced by the methods of the invention can be used for therapeutic purposes, such as in transplantation or insertion of such cells to a

person in need thereof. They would provide a good cell base for such activities, especially due to the ease in which they can be generated and proliferated and their homogeneity.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

BRIEF DESCRIPTION OF THE FIGURES

The invention will now be described in relation to the drawings in which:

Figure 1A is a graph showing the neural sphere colony forming ability of embryonic stem (ES) cells cultured at 20 cells/ul in chemically defined serum free media in the presence of various cytokines and growth factors and combinations thereof. The inset shows a light microscope photograph of an ES cell derived neural colony after 7 days in culture.

Figure 1B is a graph showing limiting dilution analysis of the frequency of neural sphere colony formation from ES cells in the presence of LIF.

Figure 1C shows inverted fluorescence microscope photographs of differentiated ES cell-derived sphere colonies, immunocytochemically labelled for the neural precursor marker nestin after 3 or 7 days in vitro.

Figure 1D is a graph showing the secondary, tertiary and quaternary neural stem cell colony forming ability of cells dissociated from primary neural colonies and cultured in the presence of exogenous LIF, FGF2 and B27.

Figure 2A shows inverted fluorescence microscope photographs of differentiated ES cell-derived sphere colonies, immunocytochemically labelled for neural cell-specific genes MAP2 (neurons), GFAP (astrocytes) and O4 (oligodendrocytes).

Figure 2B shows RT-PCR analysis of neural and non-neural lineage gene expression in RNA extracted from primary ES cells (R1), ES cell-derived sphere colonies (SC), and positive control tissue samples (+). Listed are the Emx2, HoxB1, Six3 and Otx1 markers for
5 neural differentiation, Brachyury marker for mesoderm differentiation, GATA4 and HNF4 markers for endoderm differentiation, and CK-17 for epidermal differentiation.

Figure 3A is a graph showing the neural colony forming ability of ES cells with a homozygous null mutation (FGFR-1(-/-)) in the gene
10 encoding FGF-receptor-1, or control heterozygous ES cells (FGFR-1(+/-)).

Figure 3B is a graph showing the neural colony forming ability of ES cells cultured in the presence of anti-FGF2 antibodies.

Figure 3C is a graph showing the neural colony forming ability of
15 neural stem cells isolated from the day E9.5 forebrain and cultured in the presence of LIF and FGF2.

Figure 4A is a graph showing the neural colony forming ability of ES cells cultured in the presence of LIF and FGF2 alone or in the presence of BMP4.

20 Figure 4B is a graph showing the neural colony forming ability of ES cells cultured in the presence of LIF and FGF2 alone or in the presence of LIF and FGF2 and the BMP protein antagonist Noggin.

Figure 4C is a graph showing the neural colony forming ability of Smad4(-/-) and wildtype E14K ES cells.

25 Figure 4D is a graph showing the neural colony forming ability of ES cells cultured in the presence of LIF alone or in the presence of LIF and exogenous mouse Cerberus-like (mCer-1) protein.

Figure 5A is a table showing the proportion of ES cells cultured at low cell density that were immunoreactive for the neural precursor
30 marker nestin, the immature neuronal marker β III-tubulin, the marker NeuN, and ICM/ES cell nuclear marker Oct-4. The photographs at left shows ES cells immunocytochemically labelled for nestin, β III-tubulin, NeuN., and Oct-4

- 10 -

Figure 5B is a graph showing the proportion of either *Smad4*(-/-) or control E14K wildtype ES cells immunoreactive for the immature neuronal marker β III-tubulin. The photograph at left shows *Smad4*(-/-) ES cells immunocytochemically labelled for β III-tubulin.

5 Figure 6A shows an ultraviolet light microscope photograph of a chimeric day E9.5 mouse embryo generated using ES cell-derived neural colonies harbouring a yellow fluorescent protein transgene and a CD1 host morula. The inset shows a normally developed blastocyst after 24 hours in vitro from the aggregation of a yellow fluorescent
10 protein ES cell neural colony and a CD1 host morula.

Figure 6B shows a light microscope photograph of a mouse blastocyst (arrow) and an unintegrated day E9.5 telencephalon-derived sphere colony expressing green fluorescent protein, 24 hours after the attempted aggregation of the two.

15 Figure 6C shows a light microscope photograph of the mouse embryo (arrow) developed from the blastocyst shown in Figure 6B.

Figures 7A-D are photographs of well-circumscribed clusters of cells. Figures 7 A and B depict cells which do not express nestin (arrow in A and B) that resemble typical undifferentiated ES cell colonies.
20 These aggregated cells express the undifferentiated ES cell-specific marker SSEA-1 (arrowheads in C and D). Moreover, the relatively large cells that resemble nestin-positive cells do not express SSEA-1 (arrow in C and D).

Figure 7E is a diagram showing a model of the establishment of
25 the early neural cell lineage from ES cells.

DETAILED DESCRIPTION OF THE INVENTION

As mentioned above the present inventors have invented a novel primitive neural stem cell and associated methods for differentiating embryonic stem cells toward neural cells under completely defined
30 media conditions, and methods of use of the new stem cell and methods of differentiation. As the novel primitive neural stem cell is pluripotent, it can potentially differentiate into cell types other than neural cells.

The present invention arose in part from an investigation into whether a default mechanism of neural specification could regulate the acquisition of mammalian neural stem cell identity directly from totipotent vertebrate cells.

5 Experiments were conducted to determine whether a default-like mechanism underlies neural specification in uncommitted mammalian embryonic stem (ES) cells.

In a preferred embodiment, the results indicate that chemically defined serum-free, feeder layer-free, low-density culture conditions are
10 sufficient for neural differentiation of ES cells. That a novel colony-forming primitive neural stem cell population was identified displaying properties that are intermediate to ES cells and forebrain neural stem cells. Furthermore, the results indicate that the transition from ES cell to primitive neural stem cell can be enhanced by the inhibition of TGF β -
15 related signaling, in a manner that is consistent with a default model of neural fate specification.

ES Cells

As used in the present specification, "pluripotent ES cells" and "ES cells" are those which retain the developmental potential to
20 differentiate into all somatic and germ cell lineages. ES cells may be derived from the inner cell mass (ICM) of the pre-implantation mammalian embryo and may be sustained in an undifferentiated state in vitro while maintaining ICM characteristics.

EB as used herein refers to embryoid body. The cells in an
25 embryoid body are not homogenous and are difficult to propagate.

Neurospheres refers to multicellular bodies with neural markers. They can be a source of a fairly homogenous group of cells. Most cells in a neurosphere are progenitor cells. In one embodiment, they comprise less than 1% of original stem cells. Cells of a neurosphere
30 can be used to develop new spheres that comprise cells that are usually further down the differentiation pathway. Again they also comprise copies of cells from the original neurosphere. As such cells from neurospheres can be propagated.

Culture Media

As will be appreciated by those skilled in the art, "culturing the ES cells", means culturing the cells under conditions which allow for the survival of the cells for a length of time sufficient to allow for experimentation and further use of the cells. The culturing of the cells at low density in the serum-free media, includes the understanding that the conditions under which the cells are cultured are appropriate for the continued survival of the cells for the purposes for which the cells are being used.

Standard culture media typically contains a variety of essential components required for cell viability, including inorganic salts, carbohydrates, hormones, essential amino acids, vitamins, and the like. In one embodiment, DMEM or F-12 is the standard culture medium, most preferably a 50/50 mixture of DMEM and F-12. It is advantageous to provide additional glutamine, preferably at about 2mM. Preferably, the conditions for culturing should be as close to physiological as possible. The pH of the culture medium is typically between 6-8, preferably about 7, most preferably about 7.4. In respect of pH, the term "about" means the pH mentioned plus or minus 0.5 pH units.

Cells are typically cultured between about 30-40°C, preferably between about 32-38°C, most preferably between about 35-37°C. In respect of temperature, the term "about" means the temperature mentioned plus or minus 5 degrees celcius.

Cells are preferably grown in about 5% CO₂. In respect of percentages, the term "about" means the percentage mentioned plus or minus 0.5 percent.

Serum-free media refers to a defined media comprising effective amounts of the following components: (a) a standard culture medium without serum, known as a "defined" culture medium, such as Dulbecco's modified Eagle's medium (DMEM), F-12, or a mixture thereof (As will be readily appreciated by those skilled in the art other defined standard media such as, for examples, Iscove's Modified Dulbecco's Medium (IMDM), RPMI, Fischer's, Alpha Medium, Leibovitz's,

- 13 -

L-15, Nctc, F-10, MEM And McCoy's may be used); (b) a suitable carbohydrate source, such as glucose; (c) a buffer such as MOPS, HEPES or Tris, preferably HEPES with glutamine and sodium bicarbonate; and (d) a source of hormones and salt including insulin, transferrin, progesterone, putrescine and selenium.

Cytokines

According to the present invention serum-free media may also be supplemented with one or more cytokines, and one or more growth factors that stimulate proliferation of cells. Cytokines comprise a diverse group of small proteins that mediate cell signaling/communication. They exert their biological functions through specific receptors expressed on the surface of target cells, and include but are not necessarily limited to leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), growth hormone (GH), erythropoietin (EPO), granulocyte/macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), oncostatin-M (OSM), prolactin (PRL), interleukin (IL)-2, IL-3 IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, and IL-12, interferons (IFN)-alpha, -beta and -gamma, tumor necrosis factor (TNF)-alpha, nerve growth factor (NGF), platelet factor (PF)4, platelet basic protein (PBP) and macrophage inflammatory protein (MIP)1-alpha and -beta, among others.

Growth Factors

The term "fibroblast growth factor" or "FGF" includes any protein or polypeptide having FGF biological activity, such as binding to FGF receptors, which activity has been used to characterize various FGFs, including, but not limited to acidic FGF, basic FGF, FGF2, Int-2, hst/K-FGF, FGF-5, FGF-6 and KGF.

ES Cell Differentiation

ES cell differentiation assays typically involve the formation of embryoid bodies (EB) (Martin et al., 1977; Coucovanis and Martin, 1995) that are generated from the aggregation of numerous ES cells in the presence of serum and in the absence of LIF, a factor which normally prevents differentiation. EB resemble early embryos: in the

interior, EB contain ectodermal and mesodermal tissue surrounding a cystic cavity, while externally, EB are encapsulated by primitive endoderm (Coucouvanis and Martin, 1995; 1999). Given that EB formation in very high-density cultures (25-75 times greater than the densities used in the present study) contains many different cell types (derived from all three germ layers) and are generated in the presence of 10-20% serum (which contains undefined factors), EB formation precludes a more direct analysis of the mechanisms regulating the differentiation of a specific cell lineage. Indeed, consideration of cell density and culture media parameters in studies using dissociated *Xenopus* ectodermal cells (discussed above) initiated a significant change in the understanding of vertebrate neural patterning.

The derivation of neural cells (among other cell types) from EB derived cells in vitro has been previously documented (Doetschman et al., 1985). Several studies have shown that the differentiation of neurons and glial precursors from EB derived cells can be enriched in the presence of retinoic acid (Bain et al., 1995; Fraichad et al., 1995; Strubing et al., 1995), FGF2 (Okabe et al., 1996), or PDGF (Brustle et al., 1999). Also, BMP4 has been shown to suppress neuronal differentiation of EB derived cells (Finley et al., 1999). Although these observations clearly demonstrate the potency of such factors to promote or attenuate neuronal differentiation of ES cells, each experiment was preceded by EB formation in the presence of serum. Here it is present an alternative and specific paradigm for neural cell fate specification directly from ES cells. Neural colonies can develop from ES cells in serum-free conditions in the absence of EB formation, and many single ES cells can adopt a neural (nestin⁺) or neuronal (β III-tubulin⁺) phenotype in the absence of exogenous growth factors. The derivation of neural cells from ES cells is preferably carried out at relatively low cell densities in serum-free media. Low cell density as used herein refers to a cell culture density at which cell proliferation can occur with minimal and preferably no aggregation of ES cells or EB formation. Such densities are preferably about 50 or fewer cells/ μ l, most preferably less than 20

- 15 -

cells/ μ l, and even more preferred 10 or fewer cells/ μ l. It has been shown and a person skilled in the art would understand that the invention requires at least 1 cell to work, as such a cell density of greater than 0 is required. The present inventors have found (data not shown) that

5 methods of the invention work significantly better in conditions where at about 10 or fewer cells/ μ l. Such a density results in a more homogenous cell culture i.e., primitive neural and neural cells as the case may be. The inventors have found that at this cell density, early mesodermal markers flk1 and brachyury are not expressed in the

10 neurospheres derived clonally at lower densities from the novel single primitive neural stem cells of the invention. At higher densities, there is a greater likelihood that some, but not necessarily all e that form form by aggregation of ES cells that then differentiate to multiple tissue lineages and express the early mesodermal markers as noted above.

15 The experiments conducted by the inventors (data not shown) showed that single ES cells at such low densities will become neural stem cells. This is known because the single cells clonally proliferated to form spheres of 10,000 to 15,000 cells, all of which stained for an early ectodermal marker (nestin) and which do not express markers of

20 other types of tissue like mesoderm, such as flk and brachyury. When a single sphere, clonally derived from a single primitive neural stem cell (the novel cell of the invention that comes from the neural differentiation of a single undifferentiated ES cell), is dissociated the small number of neural stem cells in the sphere (that come from the symmetrical

25 division of the original primitive neural stem cell) will proliferate to form secondary neurospheres (thus demonstrating self-renewal) that again all stain for the early neural marker nestin. In additional data (not shown), these new cells were determined not to be a tissue culture artifact but actually detectable in fembryonic day 6 and 7 epiblast in the

30 mouse. These cells can be isolated by their ability to form neurospheres in the in the presence of LIF (and not FGF2). At embryonic day 8 in the mouse, FGF2 dependent neural stem cell can be isolated from the developing neural plate.

The novel primitive neural stem cells of the invention (the LIF dependent cells) have a much greater degree of pluripotential fates than do the definitive neural stem cells isolated in similar in vitro neurosphere assays from embryonic or adult brain.

5 **Other Uses of the Cells and of the Method of the Invention**

The methods and novel primitive neural cell of the invention have many different application, especially in the field of tissue engineering, transplantation therapy and drug discovery.

10 In one embodiment, this paradigm may be useful in analyzing the role of single genes in the regulation of neural fate specification. For instance, the utilization of an expression-based gene trap library of ES cell lines (Stanford et al., 1998) offers a unique opportunity to employ a strategy for isolating genes that positively and negatively regulate the transition from an ES cell to a neural cell (Seaberg et al., 1999). Thus,
15 the present findings underscore the potential for using ES cell models of mammalian neural development.

20 The present methods and novel cell line of the invention can be used to screen potential modulators of cellular differentiation, preferably neural differentiation, but not necessarily so. As the primitive neural cells of the invention are pluripotent and can differentiate into cell types other than neural cell types under suitable conditions. The term "modulators" as used herein refers to any molecule or factor (such as
25 pH, Temperature, Time, isotonic conditions, etc) that can potentially effect cellular differentiation.

25 In one assay for screening modulators of cellular differentiation the pluripotent ES cells can be cultured under serum free, low density conditions in the presence or absence of LIF, in the presence of the modulator, and in the presence or absence of FGF2, as the situation requires, and the effect on differentiation can be detected.

30 One can also use the methods and cells of the invention to study conditions associated with cellular development and screen for potential therapeutic or corrective drugs or modulators of the condition. This can be carried out in one embodiment by comparing the

- 17 -

development of normal ES cells with cells from those having the condition.

The present inventors have identified the primitive neural stem cells in vivo, as such it is suitable for simulating an in vivo model. In one embodiment the novel primitive stem cell is LIF dependent. In another embodiment it is pluripotent. Such cells can be used in assays for drug discovery, screening for drugs and differentiation (modulating) factors, etc.. They can also be used as a good source of a relatively homogenous cell base. They can be used themselves in the treatment, or therapy of certain conditions such as in transplantation therapies, especially for conditions of neurological system, resulting in neural cell damage or loss (paralysis (regeneration of neural connections), parkinson's disease, alzheimers, multiple sclerosis). Due their pluripotency, they can also be used in developing tissues, neural or otherwise. Such tissues could be used in transplantation therapy for conditions other than those related to the neural system. For instance, the cells of the invention could be used to develop insulin producing cells for the treatment of diabetes. The cells could also be used to develop a desired cell type by propagating them under predetermined conditions conducive to development of such cell type. The cells can also be used to determine what these conditions may be. Various conditions for ES cell differentiation into multiple cell types can be found in J. Yamashita et al Nature 408 page 92.

In studying modulators of cellular differentiation, the novel cells of the invention can be cultured in the absence or presence of FGF-2 and the potential modulator, to determine the effect of the modulator on neural cell development.

The following non-limiting examples are further illustrations of the invention of the present specification.

30

EXAMPLES

GENERAL MATERIALS AND METHODS FOR THE EXAMPLES

Propagation and maintenance of ES cells

The ES cell line R1 was grown on mitotically inactive fibroblast

- 18 -

feeder layers maintained in DMEM + 10% FCS culture medium containing LIF (1000 U/ml) at low passage number (6-11) as previously described (Nagy and Rossant, 1993). For passaging ES cells, cultures were disaggregated with 0.05% trypsin dissolved in Tris-saline/EDTA
5 for 5-10 minutes, mechanically dissociated, centrifuged and resuspended in culture medium.

Culturing ES cells

Passaged ES cells were washed (2 times), centrifuged and resuspended in chemically defined serum-free media (Reynolds et al.,
10 1992; Reynolds & Weiss, 1996) composed of a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM; GIBCO) and F-12 nutrient (GIBCO) including 0.6% glucose (Sigma), 2 mM glutamine (GIBCO), 3 mM sodium bicarbonate (Sigma), and 5 mM HEPES buffer (Sigma). A defined hormone and salt mixture (Sigma) that included insulin (25
15 (g/ml), transferrin (100 (g/ml), progesterone (20 nM), putrescine (60 (M), and selenium chloride (30 nM) was used instead of serum. ES cells were plated at various cell densities in 24-well culture plates (Nunc) in the presence of either LIF (1000 U/ml), LIF + FGF2 (10 ng/ml; Upstate Biotech or Sigma) and 2 (g/ml heparin (Sigma), or in the absence of any
20 exogenous growth factors. For short term (4-24 hours) neural differentiation, ES cells were plated in identical culture conditions in 24-well culture plates (Nunc) that were precoated with poly-L-ornithine (15 µg/ml, Gibco).

Limiting dilution analysis was performed as previously described
25 (Bellows and Aubin, 1989; Tropepe et al., 1999). ES cells were plated in 24-well plates containing LIF (1000U/ml). Cell numbers were adjusted to give a starting concentration of 5000 cells/ml from which serial dilutions were made. Final cell dilutions ranged from 1000 cells per well to 1 cell per well in 0.5 ml aliquots. Cultures were left undisturbed for 7
30 days after which time the fraction of wells not containing sphere colonies for each cell plating density was calculated and those points were plotted against the number of cells plated per well. The number of cells required to form one sphere colony, which reflected the proportion

of neural stem cells in the entire population, was then determined from the point at which the regression line crossed the 0.37 level (37%). That is $F_0 = e^{-x}$, where F_0 is the fraction of wells without sphere colonies and x is the mean number of cells per well. Based on a Poisson distribution of cells, $F_0 = 0.37$ corresponds to the dilution at which there is one neural stem cell per well. The linear relationship observed between the cell density and the number of sphere colonies generated (regression coefficient $R^2 = 0.99$) can be accounted for by the clonal proliferation of a single rare population of cells.

To assess colony formation at clonal densities, ES cells were plated in serum-free media containing LIF (as above) at 5×10^4 cells per 94 mm Greiner hybridoma tissue culture dish (Fedoroff et al., 1997), which is subdivided into approximately 700 microwells, 0.04 cm^2 each (Greiner Labortechnik, Bellco Glass, Inc., Vineland, NJ). Using this procedure, microwells contained ~15 viable cells per well (randomly assorted). Cultures were maintained for a 7-day period.

Self-renewal of primary colony-forming ES cells was assessed as previously described (Trobepe et al., 1999). Single sphere colonies were isolated, mechanically dissociated into a single cell suspension in 0.2 ml of serum-free media containing various combinations of LIF (1000 U/ml), FGF2 (10 ng/ml), heparin (2 (g/ml), EGF (20 ng/ml; Upstate Biotech) or B27 supplement (1X) and cultured in 96-well (Nunc) plates. Secondary sphere colonies were quantified after 7-10 days. A similar procedure was used for repeated passaging experiments. Cell viability after a 7-day culture period (sphere colony assay) or after 4-24 hours (short-term ES differentiation assay) was determined using trypan blue exclusion (1:2 dilution of 0.4% trypan blue; Gibco).

To determine the effect of a targeted null mutation in the *Smad4* gene on neural colony formation, clones C8-13 (-/-), C8-24 (-/-), F9-2 (-/-), F9-5 (-/-) and the wildtype E14K (+/+) ES cell lines (Sirard et al., 1998) were used. There were no differences in colony formation between the various (-/-) ES cell clones and thus the analysis included

- 20 -

the pooled results from all of the clones. Human recombinant BMP4 protein (stock 0.812 mg/ml) was provided by Genetics Institute Inc. and human recombinant Noggin protein (stock 1.05 mg/ml) was provided by Regeneron Pharmaceuticals Inc.

5 Embryonic and adult dissections

Adult or Pregnant CD1 mice (Charles River, Quebec) of gestational age 9.5 (E9.5) or E14.5 (see below) dissected as previously described (Chiasson et al., 1999; Tropepe et al., 1999). In order to assess positive immunolabeling, E14.5 dissections of embryonic brain and skin were prepared as above and plated on a MATRIGEL substrate at high cell densities (~100 cells/ml) in the same culture media containing 1% FBS. For RT-PCR analyses, tissues (e.g. brain, somite, liver, footpad epidermis) that served as positive controls were dissected and enzymatically treated in a similar fashion prior to RNA extraction.

15 Embryonic and adult forebrain dissections

Pregnant CD1 mice (Charles River, Quebec) of gestational age 9.5 (E9.5) or E14.5 (see below) were killed via cervical dislocation and embryos were removed as previously described (Chiasson et al., 1999; Tropepe et al., 1999). Dissected germinal zone from the E9.5 telencephalon was transferred to serum-free media and mechanically dissociated into a cell suspension with a fire-polished Pasteur pipette. Cell viability was assessed using trypan blue. Cells were plated at 10 cells/ μ l in 24-well (0.5 ml/well) uncoated plates (Nunc) in serum-free media containing either FGF2 (10 ng/ml) + heparin (2 (g/ml) or FGF2 + heparin + LIF (1000U/ml). Self-renewal of neural stem cells that generated primary sphere colonies (selecting mainly floating colonies after 7 days in vitro) were routinely subcloned by mechanically dissociating a single colony in 0.2 ml of serum-free media, in identical growth factor conditions as the primary culture, and plated in uncoated 96-well (0.2 ml/well) plates (Nunc). The number of new secondary colonies was quantified after a further 6-7 days in vitro. Neural stem cell colonies from the adult forebrain subependyma were isolated as previously described (Chiasson et al., 1999) and cultured as above.

Immunocytochemistry

Single sphere colonies were transferred to a well coated with MATRIGEL basement membrane matrix (15.1 mg/ml stock solution diluted 1:25 in serum-free media; Becton-Dickinson) in individual wells of a 24-well culture plate (Nunc) (0.5 ml/well). Immunocytochemistry was performed as previously described (Tropepe et al., 1999). For nestin immunolabeling, sphere colonies were allowed to adhere for 24 hours in serum-free media prior to fixation. Adherent colonies were fixed with 4% paraformaldehyde in PBS (pH 7.2) for 20 min at room temperature and then washed (3x) with PBS (5 min each). Colonies were then permeabilized with 0.3% Triton X-100 for 5 min, washed (2x) with PBS (5 min each) and then incubated for 1 hour in 10% normal goat serum (NGS) at room temperature in order to presaturate non-specific protein binding sites. A rabbit polyclonal antiserum (a gift from Dr. R. McKay) (Tohyama et al., 1992) was diluted to 1:1000 (in PBS + 10% NGS) and colonies were incubated overnight at 4°C. The next day, sphere colonies were washed (3x) in PBS (5 min each) and subsequently incubated with a secondary goat anti-rabbit FITC-conjugated antibody (1:200; Sigma) for 30 min at 37°C. After rinsing three times (5 minutes each), all cultures were incubated in Hoechst 33258 nuclear stain (0.015 mg/ml stock solution diluted to 0.001 mg/ml; Boehringer Mannheim) for 5 minutes at room temperature in order to facilitate cell quantification. After washing (3x) (5 min each), colonies were coated with Fluor-mount mounting medium. Fluorescence was detected on a Nikon inverted fluorescence microscope. A similar procedure was used for longer-term differentiation of sphere colony cells. After 7 days in culture, colonies that were spread out on the substrate were fixed in 4% paraformaldehyde (in PBS, pH 7.2) for 20 minutes at room temperature followed by 3 (5 minutes each) washes in PBS (pH 7.2). Cells were then permeabilized for 5 minutes in PBS containing 0.3% Triton-X, rinsed for 5 min (2x) in PBS and blocked for 1 hour in PBS containing 10% normal goat serum (NGS). After blocking, cultures were incubated in anti-MAP-2 mouse monoclonal (IgG) (1:1000; Boehringer Mannheim)

- 22 -

and anti-GFAP rabbit polyclonal (IgG) (1:400; Chemicon) antibodies diluted in PBS containing 10% NGS over night at 4°. Cultures were then rinsed in PBS three times (5 minutes each) and subsequently incubated in FITC goat anti-rabbit (1:200; Jackson ImmunoResearch) and TRITC goat anti-mouse (1:200; Jackson ImmunoResearch) secondary antibodies at 37°C for 30 min. Cultures were rinsed three times (5 minutes each) in PBS. Separate cultures (from similar conditions) were used for oligodendrocyte immunolabelling. Cultures were incubated in anti-O4 mouse monoclonal (IgM) antibody (1:40; Boehringer Mannheim) in PBS containing 10% NGS at 4°C overnight. The next day, cultures were rinsed three times (5 minutes each) and subsequently incubated in DTAF goat anti-mouse-IgM (1:200; Jackson ImmunoResearch) secondary antibody in PBS containing 10% NGS at 37°C for 30 minutes. After rinsing three times (5 minutes each), all cultures were incubated in Hoechst 33258 nuclear stain (0.015 mg/ml stock solution diluted to 0.001 mg/ml; Boehringer Mannheim) for 5 minutes at room temperature in order to facilitate cell quantification. Colonies were washed (3x) in PBS (5 min each) and then coated with Fluormount and fluorescence was visualized using a Nikon inverted-fluorescence microscope. Secondary antibody-only control cultures were processed simultaneously using the identical protocol except dilution solutions were devoid of primary antibodies. All secondary controls were negative for immunolabeling.

For short-term (24 hours) differentiation experiments, ES cells were adhered to a poly-L-ornithine substrate (15 µg/ml; Sigma), fixed in 4% paraformaldehyde (as above) and immunolabeled using primary mouse monoclonal anti-βIII-tubulin antibody (1:1000; Sigma), anti-nestin antibody (as above) and rabbit anti-mouse Oct-4 antibody (1:400; a gift from Dr. J. Cross). Cultures were counter-labeled with Hoechst (as above) and quantified by counting 3-4 random standardized areas (using an ocular grid) at 20X objective magnification per culture.

To cryosection ES derived or forebrain derived sphere colonies, colonies were rinsed (2x) by transferring to PBS (pH 7.2) for a few

- 23 -

seconds with a Pasteur pipette. Colonies were then transferred to 4% paraformaldehyde containing 0.4% picric acid in 0.16 M phosphate-buffer (pH 6.9) and fixed for 1 hour at room temperature. Sphere colonies were then rinsed (3x) in 10 mM PBS for 5 min each
5 prior to being resuspended in 10% sucrose (in 10 mM PBS) overnight at 4°C. The following day, sphere colonies were placed in tissue freezing media (Tissue Tek) in order to quick freeze to -50°C. Using a cryostat, 14 µm sections were taken and collected on gelatin coated slides. Slides were stored at -70°C and subsequently processed for nestin or
10 nuclear Oct4 immunolabeling (as above).

RT-PCR analysis

Total RNA was isolated using the RNeasy extraction kit (Qiagen) and 1 µg of total RNA was used to synthesize cDNA with oligo-d(T)₁₂₋₁₈ primers and MuMLV reverse transcriptase (Superscript II;
15 Boehringer-Mannheim) at 42°C for 1 hour. The PCR reaction mixture (20 µl) consisted of 1 µl cDNA, 16 pmol 5' primer, 16 pmol 3' primer, specific for the gene in question 0.2 mM dNTP, 2 µl PCR reaction buffer and 0.8 U of Taq polymerase (Promega). cDNA was amplified in a thermal cycler (Perkin-Elmer). For all primer pairs denaturation for 30
20 sec at 94°C, annealing for 30 sec and extension at 72°C was used. The sense and antisense primers, Mg²⁺ concentration, annealing temperature, extension time and number of PCR cycles were used for the following genes. *Emx2*: sense 5'-GTCCCAGCTTTTAAGGCTAGA-3' (SEQ. ID. No. 1), antisense 5'-CTTTTGCCTTTTGAATTCGTTTC-3' (SEQ.
25 ID. No. 2), 1.65 mM Mg²⁺, 56°C, 40 sec, 40 cycles. *HoxB1*: sense 5'-CCGGACCTTCGACTGGATG-3' (SEQ. ID. No. 3), antisense 5'-GGTCAGAGGCATCTCCAGC-3' (SEQ. ID. No. 4), 1.35 mM Mg²⁺, 58°C, 40 sec, 40 cycles. *Otx1*: sense 5'-TCACAGCTGGACGTGCTCGA-3' (SEQ. ID. No. 5), antisense 5'-GCGGCGGTTCTTGAACCAAA-3' (SEQ. ID. No.
30 6), 1.65 mM Mg²⁺, 58°C, 40 sec, 40 cycles. *Six3*: sense 5'-CGCGACCTGTACCACATCCT-3' (SEQ. ID. No. 7), antisense 5'-GCCTTGGCTATCATACGTCA-3' (SEQ. ID. No. 8), 1.35 mM Mg²⁺, 56°C, 40 sec, 40 cycles. *B rachyury*: sense

5'-AGTATGAACCTCGGATTAC-3'(SEQ. ID. No. 9), antisense
 5'-CCGGTTGTTACAAGTCTCAG-3'(SEQ. ID. No. 10), 1.65 mM Mg²⁺,
 56°C, 1 min, 35 cycles. *GATA4*: sense
 5'-AGCCTACATGGCCGACGTGG-3'(SEQ. ID. No. 11) antisense
 5 5'-TCAGCCAGGACCAGGCTGTT-3'(SEQ. ID. No. 12), 1.35 mM Mg²⁺,
 58°C, 1 min, 35 cycles. *HN4*: sense
 5'-CCATGGTGTAAAGGACGTGC-3'(SEQ. ID. No. 13), antisense
 5'-TAGGATTCAGATCCCGAGCC-3',(SEQ. ID. No. 14) 1.35 mM Mg²⁺,
 56°C, 1 min, 35 cycles. **CK-17, sense (SEQ.ID.No), antisense**
 10 **(SEQ.ID.No.)** As a control, cDNA amplification of the *GAPD* gene
 (glyceraldehyde-3-phosphate dehydrogenase) was simultaneously run
 in each PCR experiment. Primers for *GAPDH*: sense
 5'-ACCACAGTCCATGCCATCAC-3'(SEQ. ID. No. 15), antisense
 5'-TCCACCACCCTGTTGCTGTA-3'(SEQ. ID. No. 16) and PCR reaction
 15 conditions were similar to conditions used for *Emx1* amplification (see
 above). Amplified products were electrophoresed in 2% agarose gel
 containing ethidium bromide (25 µg/ml) and bands were visualized with
 UV light (DualLite Transilluminator, Fisher Biotech).

Expression of mouse *Cerberus-like* in Neuro2a cells

20 Neuro2a (a murine neuroblastoma cell line) cells were seeded at
 1 x 10⁶ cells per 100 mm petri dish and transiently transfected with 10
 µg of plasmid DNA by means of LipofectAMINE (Gibco) according to the
 manufacturer's instructions. After 6 hours, the culture media was
 changed to 10 ml of DMEM+10% FBS (Gibco). Twenty-four hours after
 25 transfection, culture media was changed to 10 ml of serum-free media.
 Seventy-two hours after transfection, cell supernatant was collected and
 centrifuged to remove cellular debris. Supernatant media was aliquoted
 and stored at -70°C. Addition of 4% (v/v) of supernatant (3 separate
 experiments) resulted in a similar increase in colony formation
 30 compared to the addition of 20% (v/v) supernatant (2 separate
 experiments), but this effect was considerably variable from one
 experiment to the next, whereas addition of 20% (v/v) supernatant
 resulted in a very consistent increase between experiments. Thus data

from the 20% (v/v) experiments were used for the analysis. The plasmids pCS-V2 (gift from Dr. R. Moon) (Hoppler et al., 1996) and pCS-*cer-1* (a gift from Dr. E. De Robertis) (Belo et al., 1997) were used.

Generation of chimeras

5 ES sphere colonies were generated using ES cells harboring a yellow-fluorescent protein (YFP) transgene or cyan-fluorescent protein (CFP) transgene (gifts from Drs K. Hadjantonakis and A. Nagy). Embryonic or adult telencephalon-derived sphere colonies were generated from either green fluorescent protein (GFP) transgenic mice
10 (a gift from Drs. K. Hadjantonakis and A. Nagy) or ROSA mice ubiquitously expressing the LacZ gene product β -galactosidase (β -gal) (Jackson Laboratory) (Friedrich and Soriano, 1991). ES-derived, E9.5, E14.5 or adult telencephalon-derived sphere colonies were aggregated with diploid CD1 morula-stage embryos for 24 hours in vitro as
15 previously described (Nagy and Rossant, 1993). Once integrated, the colony-embryo aggregates were then transferred into pseudo-pregnant CD1 females, harvested at embryonic day E8.5-E9.5 and either stained for β -gal activity (for ROSA-CD1 chimeras) or visualized for fluorescence (GFP-CD1 chimeras). β -gal activity was detected by rinsing embryos in
20 a 100 mM sodium phosphate buffer (pH 7.3), fixing in 0.2% glutaraldehyde, 2 mM MgCl_2 , 5 mM EGTA and 100 mM sodium phosphate (pH 7.3) at room temperature for ~15 min. Embryos were then rinsed (3x) in a wash buffer containing 0.02% NP-40, 0.01% deoxycholate, 2 mM MgCl_2 , and 100 mM sodium phosphate (pH 7.3) for
25 ~10 min each. Embryos were stained in 1 mg/ml X-gal, 5 mM $\text{K}_3\text{Fe}(\text{CN})_6$, 5 mM $\text{K}_4\text{Fe}(\text{CN})_6$, 0.02% NP-40, 0.01% deoxycholate, 2 mM MgCl_2 , and 100 mM sodium phosphate buffer (pH 7.3) at 37°C overnight.

Example 1

30 **Single ES cells differentiate into colony forming neural stem cells in the absence of serum, feeder layers or the formation of EB**

To determine directly the capacity for ES cells to adopt a neural

fate in the absence of serum-derived or feeder layer-derived factors and in the absence of cell-cell contact found in embryoid bodies, ES cells were cultured at relatively low cell densities in a chemically-defined, serum-free media. Under similar conditions, single neural stem cells isolated from the embryonic germinal zone of the neural tube can proliferate in response to exogenous EGF or FGF2 to give rise to clonal colonies of undifferentiated neural precursor cells that form floating spheres (Reynolds et al., 1992; Tropepe et al., 1999). The colony-forming neural stem cells have the classical stem cell properties of self-renewal and multipotentiality (Potten and Loeffler, 1990; Morrison et al., 1997). That is, a small percentage of cells isolated from single dissociated colonies can generate new clonal colonies (self-renewal), while the majority of cells within the colonies will differentiate into either neurons and glia, astrocytes or oligodendrocytes, (Reynolds and Weiss, 1996).

When ES cells were cultured at relatively low cell densities in the presence of either EGF or FGF2 or in the absence of exogenous growth factors, no cell colonies were generated (Figure 1A). In contrast, in the presence of exogenous leukemia inhibitory factor (LIF), which is normally used to maintain ES cells in an undifferentiated state (Smith et al., 1988; Williams et al., 1988), floating sphere-like colonies were generated after 7 days in vitro. There was no significant difference in the numbers of neural stem cell colonies generated when either EGF or FGF2 were combined with LIF compared to LIF alone, although the presence of FGF2 produced a non-significant trend toward facilitating LIF-dependent colony formation (Figure 1A). Thus, exogenous EGF and FGF2 were neither necessary nor sufficient for colony formation in primary cell cultures. Furthermore, CNTF, another member of the cytokine family of signaling molecules to which LIF belongs (Kishimoto et al., 1994), was unable to substitute as a colony-promoting factor (data not shown), suggesting that the effects of LIF are specific.

To determine the frequency of cell colony formation, ES cells were cultured at various cell densities (from 1 cell/well to 20 cells/ μ l) in

- 27 -

24-well culture dishes in a limiting dilution assay (Bellows and Aubin, 1989; Tropepe et al., 1999). The estimated frequency of sphere colony forming cells in the presence of LIF was ~0.2% (Figure 1B). No sphere colonies were observed at cell densities of less than 500 cells per well (0.5 ml of media), suggesting that a threshold number of cells may be required in order to facilitate the clonal proliferation of a single ES cell. However, it was found that the present invention would work with even a single cell. To show this, ES cells were cultured at ~15 cells per microwell randomly distributed in Greiner hybridoma culture dishes subdivided into 700 microwells (0.04 cm² each). Even though the majority of microwells contained cells, an average of 35 colonies were generated (2 separate cultures) over the entire dish. Hence, a similar frequency of sphere colony formation was observed over the entire culture dish (i.e. 15x700 = 10,500 cells; an average of 35 colonies (10,500 = 0.3%). Furthermore, in one additional experiment, single ES cells were cultured in 96-well plates (0.2 ml) and 1 sphere colony was generated in 600-700 wells scored. Thus, the results demonstrate that a very small percentage of single ES cells generate sphere colonies under these conditions as predicted by the limiting dilution analysis.

20 **Example 2**

Colony-forming ES cells show neural stem cell characteristics

Sphere colonies generated in the presence of LIF grew to a size of approximately 300-500 µm in diameter after 7 days and were composed of cells that all expressed the intermediate filament protein nestin, which is expressed in neural precursor cells in embryonic and adult CNS tissues and transiently in muscle progenitors (Lendahl et al., 1990) and in some epithelial derivatives (Mokry and Nemecek, 1998) (Figure 1C). An analysis of smaller sized colonies identifiable at 3 days in culture (composed of 20-30 cells) demonstrated that all of the cells within these colonies (determined by counting Hoechst stained nuclei) appeared to express nestin. Thus, nestin expression is correlated with the initial formation of the sphere colony, coinciding with nestin expression in single ES cells at the onset of the cell culture period prior

to sphere colony formation, and no cells within the colonies retained nuclear expression of the ES cell marker Oct-4 (see below). These data suggest that individual ES cells acquire a neural precursor cell identity before they proliferate to generate neural colonies.

5 Individual colonies were dissociated and subcloned as previously reported (Reynolds et al., 1992; Tropepe et al., 1999) in the presence of exogenous LIF, FGF2 or EGF alone, or in combinations. Regardless of the primary culture conditions the formation of secondary neural stem cell colonies was dependent upon the presence of
10 exogenous FGF2. LIF alone was not sufficient for secondary colony formation (Figure 1D). The colony-forming ability in tertiary and quaternary subcloned cell cultures could be sustained with combined FGF2 and LIF. However, substituting for LIF with a B27 media supplement (thought to prevent excessive cell death by inhibiting free
15 radical-induced cellular damage) in the FGF2 cultures was sufficient for repeatedly generating new sphere colonies (Figure 1D). Furthermore, the ability to generate sphere colonies in the presence of exogenous EGF alone, EGF + LIF or EGF + LIF + B27 was not observed and the effect of EGF + FGF2 was similar to the effects of FGF2 alone. The
20 relatively small expansion of ES sphere colonies (2-16 new clonal colonies arise from the dissociation of a single ES derived neural colony; Figure 1D) is similar to the primary subcloning of FGF-responsive neural stem cells isolated from the E8.5 anterior neural plate (Tropepe et al., 1999). Under conditions of the present invention,
25 however, new ES derived colonies maintain their FGF2 and LIF (or B27) dependence upon repeated subcloning, whereas the E8.5 derived neural stem cell colonies require only FGF2. Furthermore, a separate EGF-responsive population of colony-forming cells, which occurs during the development of the neural stem cell lineage between E10.5 and
30 E14.5 in vivo (Tropepe et al., 1999; Martens et al., 2000) was not established from the ES-derived colonies.

To determine if the individual cells giving rise to the neural colonies had neural multilineage potential, individual colonies were

encouraged to fully differentiate (placed on a MATRIGEL substrate and in the presence of 1% FBS) for a period of 7 days. Under these conditions, each of the differentiated colonies contained neurons (MAP2⁺ or β -III tubulin⁺), astrocytes (GFAP⁺) and oligodendrocytes (O4⁺) using these conventional cellular markers of differentiation (Figure 2A). The neural cells identified in these differentiated cultures (including undifferentiated, nestin⁺ cells) accounted for all of the cell types present in the colonies. At least one non-neural marker, the muscle determination gene product MyoD, was not detectable by immunocytochemistry in these colonies, even though MyoD⁺ cells were identified in control explant cultures of E9.5 somitic mesoderm (data not shown). ES cells (not from ES colonies) cultured for 7 days in the same differentiation conditions at high cell densities do not express the neuronal markers MAP2 or β -III tubulin. Thus, at relatively high all densities, ES cells must be specified to a neural identity (neural stem cell colonies) in order to differentiate into neurons and glia.

To further examine the lineage commitment of the ES-derived sphere colonies, we analyzed the expression of genes restricted to neural and non-neural lineages using RT-PCR analysis (Figure 2B). Sphere colonies did not express the early mesoderm-specific transcription factor brachyury (Beddington et al., 1992), which is abundant in EB (Elefanty et al., 1997). Sphere colonies expressed the early endodermal marker GATA4, a zinc finger transcription factor that binds to a core GATA motif in the *cis* regulatory elements of many genes (Arceci et al., 1993). However, the gene HNF-4, which is a later endodermal marker (Taraviras et al., 1994; Li et al., 2000), was not expressed in ES-derived neural colonies, suggesting only partial endodermal potential within the colonies, unlike full endodermal potential documented for EB differentiation. Consistent with this observation, the absence of Otx1, expressed during the formation of the anterior visceral endoderm and later in the forebrain (Acampora et al., 1998), suggest that sphere colonies do not engage in full visceral endoderm differentiation. Finally, the epidermal marker Cytokeratin-17

- 30 -

(McGowan and Coulombe, 1998) was not expressed in colonies.

Specific neural mRNAs were expressed in isolated ES-derived sphere colonies. The dorsal telencephalon-specific homeodomain transcription factor *Emx2* (Simeone et al., 1992), and the hindbrain and spinal cord specific transcription factor *HoxB1* (Wilkinson et al., 1989) were expressed in the ES-derived neural sphere colonies (Figure 2B). However, the anterior neural gene *Six3* (Oliver et al., 1995), like *Otx1*, was not expressed. As a control, neural colonies derived from E14.5 forebrain germinal zone were assayed for the expression of lineage-specific genes. Although neural specific gene expression was confirmed in these samples (Figure 2B) expression of the non-neural genes *brachyury*, *GATA4* and *HNF-4* was not observed (data not shown). In addition, ES cells freshly trypsinized from their feeder-layers were also used as controls. With the exception of *GATA4*, *Otx1* and *HNF4*, the unmanipulated ES cells express all of the genes tested, and indeed are known to non-specifically express a variety of genes (Elefanty et al., 1997). Interestingly, neural-specific gene expression persisted in the sphere colonies, whereas the mesodermal marker *Brachury* was downregulated in the transition from ES cells to neural colonies. Thus, sphere colonies generated through the proliferation of a single neural cell are specified to primarily a neural identity and are composed of both neuronal and glial lineages. The fact that some non-neural genes (e.g. *GATA4*) are expressed in sphere colonies may suggest that these specified neural stem cell derived colonies are not completely committed to a neural fate, but may retain pluripotent or more primitive characteristics (see below) than the neural stem cells isolated from the embryonic and adult nervous system. Furthermore, the vast majority of non-colony forming ES cells adopt a neural (and even neuronal) cell fate as early as 24 hours (see below). The absence of *Otx1*, which is expressed in the anterior neural tube and anterior visceral endoderm, further may indicate that early anterior-posterior polarity is not intrinsic to sphere colonies.

Example 3

LIF functions as a permissive factor for neural stem cell differentiation of ES cells

The ability of LIF to specifically promote neural colony formation in serum-free media (in the absence of exogenous growth factors) may indicate that LIF induces uncommitted ES cells to a neural fate in primary cultures. However, there are numerous examples in the literature where the presence of LIF was necessary to maintain ES cells in an undifferentiated state (reviewed in O'Shea, 1999), while LIF withdrawal was coincident with differentiation (e.g. Doetschman et al., 1985). Two observations in the present study suggest that LIF may act in a permissive manner to enable ES cells to adopt a neural stem cell fate.

First, since neural stem cells isolated from the E8.5 neural plate are dependent upon FGF (Trapepe et al., 1999), it was tested whether endogenous FGF signaling mediates neural colony formation in primary ES cell cultures in the presence of LIF. We utilized a FGF-receptor-1-deficient (*FGFR1*^(-/-)) ES cell line (compared to a *FGFR1*^(+/-) control cell line; Ciruna et al., 1997) and assayed for neural colony formation. In the absence of functional FGFR1 signaling, the ability of ES cells to adopt a neural stem cell fate and generate colonies after 7 days in vitro was diminished by 82% in the presence of LIF (Figure 3A), suggesting that ES cells may be responding to endogenous FGF that is released by the ES cells. Consistent with this notion, the addition of an anti-FGF2 antibody to a primary ES cell culture in the presence of LIF caused a >95% decrease in the number of neural colonies observed after 7 days (Figure 3B). These results demonstrate that although the addition of exogenous FGF2 is not necessary for neural colony formation in the presence of LIF, endogenous FGF signaling is required.

Second, exogenous LIF can enhance the numbers of FGF-responsive neural stem cells from the E9.5 forebrain that proliferate to form sphere colonies in the presence of FGF2, compared to cultures with FGF2 alone (Figure 3C), but LIF alone is not sufficient for

- 32 -

E9.5 neural stem cell proliferation. Furthermore, LIF (as well as B27) can promote the repeated subcloning of ES-sphere colonies that are FGF-dependent. These results indicate that although LIF is critical for the early transition of ES cells into colony-forming neural stem cells, it may act primarily as a permissive factor to maintain cell survival in these minimal conditions. In contrast, FGF signaling is critical at all stages of neural stem cell colony formation, but it is unclear if it is involved in the induction of the neural differentiation of ES cells or simply in promoting proliferation in our colony-forming assay.

10 **Example 4**

Inhibition of TGF β -related signaling enhances neural stem cell differentiation of ES cells

Given that very few of the cultured ES cells generated sphere colonies (~0.2%), it was sought to determine if the release of endogenous BMP from the ES cells inhibited neural sphere colony formation, as would be predicted from the neural default model. To test whether BMP could inhibit ES sphere colony formation, BMP4 (5 ng/ml) was added to ES cell cultures containing LIF and FGF2. A greater than 50% decrease in the number of sphere colonies generated was observed and this effect appeared to be maximal since a 5-fold increase in BMP4 concentration did not further significantly attenuate the number of sphere colonies generated (Figure 4A). The addition of the BMP protein antagonist Noggin (100 μ g/ml) to the primary ES cell cultures caused a 50% increase in the number of sphere colonies generated (Figure 4B). This increase appeared to be maximal since an increase in Noggin concentration from 10 μ g/ml to 100 μ g/ml resulted in no additional increase in the numbers of sphere colonies generated.

It is evident that although Noggin can enhance the numbers of ES cells that differentiate into neural colony-forming stem cells, the effect is moderate. It is possible that Noggin may eventually lose its activity and degrade with our extended culture periods. Alternatively, Noggin is known to be less effective than Chordin in neural induction assays in *Xenopus* (Lamb et al., 1993) and targeted null mutations in both Noggin

and Chordin are required to demonstrate anterior neural development deficits in mice in vivo (Bachiller et al., 2000). Thus, the moderate increase in the numbers of ES cells that will differentiate into neural sphere colony-forming stem cells in the presence of exogenous Noggin may underestimate the role for BMP-mediated inhibition of neural stem cell colony formation. Certainly, BMP4 and BMP-receptor-1 are expressed by undifferentiated ES cells (Elefanty et al., 1997). To determine more directly the effect of blocking BMP signaling, we utilized an ES cell line with a targeted null mutation in the *Smad4* gene (Sirard et al., 1998), an intracellular transducer of TGF β -related signaling (Wrana, 2000). Since *Smad4* is a critical common component for multiple TGF β -related signaling pathways, we reasoned that a null mutation in the *Smad4* gene would abrogate most of the BMP signaling that could potentially inhibit neural sphere colony formation. *Smad4*^(-/-) ES cells cultured in the presence of LIF generated a 4-5 fold increase in the numbers of neural sphere colonies, compared to the wildtype E14K cell line used to generate the targeted mutation (Figure 4C). The baseline numbers of sphere colonies generated by wildtype R1 ES cells (26.3 ± 5.4) and wildtype E14K ES cells (25.7 ± 6.7) cultured at 20 cells/ μ l were not significantly different ($t = 0.08$, $p > 0.05$). Interestingly, the rate of proliferation between wildtype and *Smad4*^(-/-) cells in high or low serum concentration is similar, indicating that the increase in the number of colonies from mutant ES cells is likely not a result of a general increase in proliferation. The increase in neural colonies in *Smad4*^(-/-) was greater than the augmented numbers of sphere colonies observed in the presence of exogenous Noggin, possibly because *Smad4* inactivation is more effective in inhibiting BMP signaling. Taken together, these results indicate that BMP4 signaling has a specific effect in limiting the numbers of single ES cells that differentiate into colony forming neural stem cells and that inhibition of this pathway is sufficient to enhance neural stem cell colony formation. Importantly, the *Smad4*^(-/-) primary neural stem cell derived colonies did not passage at a greater rate compared to control primary neural stem

cell colonies (data not shown), suggesting that the effect of the mutation is on the transition from ES cell to neural stem cell and not on the later symmetrical division of the neural stem cells.

The secreted factor Cerberus is a potent neural inducer in
5 *Xenopus* (Bouwmeester et al., 1996), [as is the mouse homologue
Cerberus-like (Belo et al., 1997)] and acts by antagonizing BMP
signaling (Pearce et al., 1999; Piccolo et al., 1999). To determine
whether Cerberus can interfere with neural stem cell commitment in
mammalian cells, we cultured primary ES cells in the presence of LIF in
10 media containing supernatant collected from transiently transfected
Neuro2a cell lines producing mouse Cerberus-like (mCer-1) protein.
The presence of 20% (v/v) of mCer-1 supernatant in 0.5 ml serum-free
media + LIF resulted in close to a 50% increase in the numbers of
primary neural stem cell colonies generated, compared to control ES
15 cell cultures containing equivalent proportions of supernatant from cell
lines similarly transfected with the backbone vector without the mCer-1
gene (Figure 4D). A similar increase in sphere colony formation was
also observed when using supernatant collected from a transiently
transfected COS7 cell line (data not shown). Again consistent with the
20 default model, mCer-1-mediated inhibition of BMP signaling can
enhance the frequency with which single ES cells differentiate into
colony forming neural stem cells. More over ES derived neural colonies
in the presnce of mCer-1 enriched media but not in the presence of the
control media, express Otx-1 (data not shown), indicating that mCER-1
25 also may anteriorize the neural colony cells. Wnt proteins are known to
inhibit neural differentiation (Harland and Gerhart, 1997) and Cerberus
can antagonize Wnt signaling (Piccolo et al., 1999). However, the effect
of exogenous mCer-1 on neural colony formation was not greater than
exogenous Noggin, and substantially less than the effect of a *Smad4*
30 mutation, suggesting that under these conditions additional Wnt
antagonism may not be required for ES-derived neural colony formation.

Example 5

Neural cell fate is rapidly established from ES cells in the absence of

exogenous factors

An analysis of neural cell differentiation from ES cells at an earlier time period in culture would facilitate a more accurate estimate of the number of ES cells that differentiate into neural cells.

5 It was predicted that if ES cells were acquiring a neural identity by default, they would express neural markers at very early stages during the culture period. To test this, ES cells (seeded at 10 cells/ μ l) were allowed to adhere to a poly-ornithine substrate and the proportion of ES cells that differentiated into neural cells after 24 hours in the absence of
10 serum and LIF was determined. After 24 hours in culture, $69.9 \pm 4.6\%$ of ES cells were non-viable in the absence of growth factors (estimated using trypan blue exclusion, $n=4$ separate culture wells). Therefore, in addition to TGF β -related inhibition, the low frequency of ES cells differentiating into neural cells may be a result of extensive cell death in
15 long-term culture assays. However, of the remaining 30% of viable cells, 82% were immunoreactive for the neuroepithelial marker nestin in the absence of growth factors (Figure 5A). Although, the percentage of viable cells after 4 hours was significantly greater (about 90%), the frequency of nestin⁺ cells at this earlier time point was similar (70-80%). The
20 majority of the nestin⁺ cells had a relatively large, flattened and irregular morphology with prominent filamentous immunolabeling within the cytoplasm. A smaller subpopulation (51%) of the nestin⁺ cells were also immunolabeled for the immature neuronal marker β III-tubulin (51%) and NeuN (29%), many of which had a relatively small soma with very
25 little perinuclear cytoplasm, and evidence for thin cytoplasmic processes resembling leading and trailing processes of a bipolar neuronal morphology (Figure 5B). The addition of LIF and FGF2 to these culture conditions did not significantly alter the percentage of ES cells that differentiated into neural cells. These data indicate that within 24 hours,
30 ES cells may be competent to directly differentiate into neural cells at low cell densities and serum-free conditions in the absence of exogenous growth factors.

A second prediction that can be made from the default model of

neural fate specification is that an increase in cell density will facilitate inhibitory intercellular communication (cells in close proximity) and attenuate the numbers of ES cells differentiating into neural cells. To test this, we cultured ES cells in identical conditions for 24 hours, but
5 increased the cell density by 5-fold (to 50 cells/ μ l). At this relatively higher cell density, the proportion of nestin⁺ cells was reduced from 82% to 40% ($t = 2.98$, $p < 0.05$) in absence of growth factors and from 70% to 51% ($t = 2.79$, $p < 0.05$) in LIF+FGF2. The proportion of β III-tubulin⁺ cells was reduced from 51% to 13% ($t = 4.07$, $p < 0.05$) in
10 absence of growth factors and from 53% to 7% ($t = 5.63$, $p < 0.05$) in LIF+FGF2 (Figure 5A, B). LIF + FGF2 did not affect the reduction in cells expressing the neural markers at higher cell densities (data not shown).

To exclude the possibility that a subpopulation of ES cells at the start of the 24-hour culture period were already committed to a neural
15 fate, we tested whether ES cells just prior to culturing expressed the ICM/ES cell nuclear marker Oct-4, a POU transcription factor (Nichols et al., 1998). After ES cells were trypsinized from their feeder layers and washed in serum-free media, the cell suspension was fixed in 4% paraformaldehyde and allowed to adhere to a poly-ornithine substrate
20 before immunolabeling with an anti-Oct-4 antibody. Using this method, all of the ES cells retained their rounded morphology and were immunoreactive for Oct-4 (localized to the nucleus), but none expressed nestin. As control, forebrain-derived sphere colony cells expressed nestin under this immunolabelling protocol, but were negative for Oct4
25 expression. Next, it was tested whether the remaining non-nestin immunoreactive population after 24 hours in our low-density cultures retained their ES cell identity. All of the non-nestin immunoreactive cells (17%) expressed nuclear Oct-4 at cell densities of 10 cells/ μ l (Figure 5C). The Oct-4⁺ cells had a rounded morphology with a thin rim of
30 perinuclear cytoplasm that was distinct from the morphology of nestin⁺ cells. Furthermore, we observed a trend toward an increase in nuclear Oct-4-immunoreactivity (up to 26%) when ES cells were cultured at a 5-fold higher cell density (Figure 5C), which was inversely proportional

to the relative decrease in nestin and β III-tubulin expression at the same high cell densities. Thus, increased cell density inhibits neural cell differentiation and may facilitate the maintenance of ES cells in an undifferentiated state.

5 **Example 6**

Neuronal differentiation is enhanced in *Smad4*^(-/-) ES cells

To determine whether TGF β signaling influences the extent to which ES cells adopt a neuronal phenotype in the short term differentiation assay, as it did the acquisition of the neural stem cell phenotype (see above), *Smad4*^(-/-) ES cells were cultured at relatively high cell densities (50 cells/ μ l) for 24 hours and double-immunolabeled for nestin and β III-tubulin. Under these conditions, neuronal differentiation from wildtype ES cells is relatively low. The number of nestin⁺ cells that differentiated from *Smad4*^(-/-) ES cells after a 24 hour culture period increased slightly, but not significantly to 71% compared to 58% in the E14K wildtype control ES cells (Figure 5D). However, a more substantial increase in β III-tubulin⁺ neurons (26%) was observed from the *Smad4*^(-/-) ES cells, compared to the E14K control ES cells (10%; $t = 2.62$, $p < 0.05$), and a greater number of the *Smad4*^(-/-) ES cells demonstrated a more elaborate neuritic morphology. Thus, at a relatively high cell density, inhibition of the BMP signaling pathway resembles increased cell dilution in its effectiveness in facilitating neural cell differentiation from ES cells.

Example 7

25 **ES-derived neural stem cell colonies contribute extensively to all embryonic tissues in chimeric mice**

Neural stem cells derived from the embryonic and adult central nervous system demonstrate neural multilineage potential (Weiss et al., 1996). Similarly, neural stem cells derived from ES cells generate progeny that are specified to a neural fate and differentiate into neurons and glia. To determine if neural stem cell colonies have a broader potential to generate non-neural lineages, we performed mouse

chimeric analyses. ES cells introduced into a blastocyst or aggregated with a morula predominantly contribute to the epiblast of the developing embryo, whereas extraembryonic tissues are primarily of host origin (Beddington and Robertson, 1989). As mentioned previously, cells within ES-derived neural colonies (adhered for 24 hours) express the undifferentiated neural marker nestin throughout all stages of colony formation. It was further determined that within 14 μ m cryosections of whole ES sphere colonies after 7 days in culture all of the cells appeared to express nestin, which is similar to nestin expression in sectioned forebrain derived neural stem cell colonies. However, no nuclear Oct4-expressing cells in ES sphere colony sections or forebrain colony sections (data not shown) were observed, suggesting that no cells within ES derived neural colonies maintained an undifferentiated ES cell phenotype.

Blastocyst-stage or morula-stage embryos were used as hosts and neural stem cell colonies derived either from: (a) embryonic or adult forebrain tissue from mice harboring a ubiquitously expressed *LacZ* transgene (ROSA) (Friedrich and Soriano, 1991) or a ubiquitously expressed green fluorescent protein transgene (GFP) (Hadjantonakis et al., 1998); or (b) ES cells harboring a yellow or cyan fluorescent protein transgene (YFP, CFP) (gifts from Drs. Hadjantonakis and Nagy). Approximately 92% (22/24) of the single YFP or CFP ES-derived colonies aggregated with morulas after 24 hours in vitro contributing to the ICM in normally developed blastocysts (Figure 6A, inset) and had substantial contribution to all embryonic tissues in embryos recovered from pseudopregnant females at E9.5 (Figure 6A). However, blastocyst injections of cells derived from E14.5 or adult ROSA neural colonies did not integrate into the ICM of the host embryos after 24 hours and in many cases tended to adhere to the host mural trophectoderm. Embryos recovered between E7.5 and E8.5 from these chimeras did not contain any *LacZ*⁺ cells (0/19). Furthermore, E14.5 ROSA or E9.5 GFP neural stem cell colonies were unable to aggregate with morulas over a 24-hour period. Neural stem cell colonies were apparently unable to

- 39 -

adhere to the host embryonic cells in the morula aggregates. Consequently, host morulae developed normally over the 24-hour culture period into healthy blastocysts while the sphere colonies remained outside of the embryo (Figure 6B, C). To test whether ES-derived sphere colonies (that readily adhere to morula cells) could facilitate the integration of colonies derived from the E9.5 forebrain, we cultured CFP ES colonies with GFP E9.5 colonies together with the host morula. In all cases, no E9.5 GFP colonies were observed to integrate (0/18), even though in many cases the CFP ES colonies did. These data suggest that ES derived neural stem cell colonies are competent to colonize many different tissues when exposed to an appropriate environment. However, this ability is only transient since neural stem cell colonies isolated from embryos in the earliest stages of neural development do not appear to have the same capacity (e.g. adhere to morula cells or integrate into ICM) to contribute to chimeric mice. Thus, the pluripotency of neural stem cells may only be evident in the earliest stages of the ES to neural transition, before the neural cells become more restricted.

EXAMPLE 8

20 Undifferentiated ES cells and differentiated neural cells are distinct populations, even in high cell density, serum-containing cultures

It is evident that even at high cell density some ES cells can start to express neural markers (e.g. Figure 2B), raising the possibility that some of the Nestin expression we are detecting at low densities after 24 hours is normally present in undifferentiated ES cells at high densities. As reported above, morphologically distinct Nestin⁺ cells were separate from Oct4⁺ undifferentiated ES cells in serum-free, low-density conditions (Figure 5). However, we further tested whether undifferentiated ES cells also expressed Nestin when cultured at high cell densities (~100 cells/ml) on a gelatin substrate in the presence of 15% FCS and LIF. After 24 hours in culture, many circumscribed undifferentiated ES cell colonies were observed, as well as separated cells distributed diffusely between the clusters. We found that the

clusters of cells with the typical undifferentiated ES cell morphology do not express Nestin (Figure 7A, B). However, separate Nestin⁺ cells ($16.1 \pm 3.4\%$ of the cells per well) were observed between clusters and their morphology resembled Nestin⁺ cells from the low cell density cultures. In contrast, cells within the clusters expressed SSEA-1 (Solter and Knowles, 1978), an ES cell specific marker ($65.3 \pm 3.9\%$ of the cells per well) (Figure 7C, D). Importantly, the population of cells expressing SSEA-1 did not overlap with the population of cells expressing Nestin, confirming the results we obtained in serum-free, low-density conditions. These findings may indicate that there is a direct phenotypic change from ES cells to neural cells. This direct phenotypic change is substantially inhibited at high cell densities, confirming our earlier experiments. There were significantly fewer ($t = 9.3$, $p < 0.05$) Nestin⁺ cells in these high density cultures than the 82% Nestin⁺ cells seen in our low density ES cultures after 24 hours (see above), again confirming our previous results of inhibition of neural differentiation with increasing cell density after 24 hours.

It is possible that in the absence of a feeder cell substrate, some ES cells can escape neural inhibition especially in cell-sparse regions of the culture. To determine whether feeder cells can maximally inhibit the neural differentiation of ES cells, we cultured CFP ES cells on a feeder layer substrate at high cell densities in the presence of 15% FCS and LIF (our typical ES cell propagation and maintenance culture conditions). Greater than 98% viability of ES cells was observed when cultured under these conditions prior to immunostaining. Furthermore, the CFP ubiquitously expressed in the ES cells allowed us to unambiguously distinguish positive immunoreactivity between ES cells and feeder cells. Under these conditions, all of the CFP⁺ ES cells expressed nuclear Oct4, but were negative for nestin expression. Similar results were observed using the SSEA-1 antibody. However, cells from embryonic forebrain derived sphere colonies cultured for two days on feeder cells were positive for nestin expression, but negative for Oct4 and SSEA-1 expression. Thus, under optimal culture conditions,

ES cells maintain an undifferentiated ES cell phenotype and express ICM/ES specific markers, but do not express nestin. We conclude that in the absence of feeder-derived or serum-derived factors and at low cell densities, ES cells undergo a direct phenotypic change towards a neural fate, which is consistent with a default mechanism of neural fate specification.

DISCUSSION OF EXAMPLES 1-8

Neural cell fate specification during mammalian development

Once the primordium of the embryo proper is established (i.e. the segregation of ES cells in the ICM from extraembryonic tissues), the formation of the neural lineage is under inhibitory control. The present findings suggest that in isolation at relatively low cell densities, ES cells have an autonomous tendency to differentiate into neural cells, but that this tendency is partially mitigated by intercellular signals (stronger at higher densities) that inhibit neural differentiation. In vivo, where cell density and neural inhibition are maximal the differentiation of the neural stem cell lineage is highly dependent on the suppression of neural inhibition. In the foregoing examples, it was demonstrated that mouse ES cells adopt either a primitive neural stem cell fate or a neuronal cell fate in the absence of exogenous serum- or feeder layer-derived signals and in the absence of cell-to-cell contact in a low cell density, chemically-defined culture environment. Furthermore, blocking TGF β -related signaling can augment the proportion of either neural stem cell colony formation or neuronal differentiation, consistent with similar neuronal differentiation evidence in a variety of vertebrate species (Sasai et al., 1995; Wilson et al., 1997; Fainsod et al., 1997; Hoodless and Hemmati-Brivanlou, 1997; Grinblat et al., 1998). It was also demonstrated that even at relatively low cell densities, ES cells secrete TGF β -related neural inhibitors (e.g. BMP4) to limit the proportion of cells adopting a neural phenotype, a process that is similarly thought to occur in the epiblast during gastrulation in vivo (Beddington and Robertson, 1999). This may explain why a decrease in cell density did not increase the proportion of ES derived primitive neural stem cell

colonies after 7 days. However, a cell density-dependent change in neural differentiation of ES cells was observed after 24 hours. It is possible that although these low-density conditions alleviate some neural inhibition (mediated primarily by TGFb signaling), colony forming primitive neural stem cells may be more sensitive to very low concentrations of TGFb. Thus, in the absence of all TGFb signaling (e.g. *Smad4*^{-/-} ES cells), enhanced primitive neural colony formation is observed. Furthermore, if a default mechanism is solely responsible for neural stem cell fate specification, then other antagonists of neural inhibition in addition to TGFb inhibitors may be required under our culture conditions in order to maximally promote an ES-to-neural default. However, the findings also suggest that the default neuralization in mammalian cells may not be homologous with default neuralization in amphibian cells.

15 In *Xenopus*, ectodermal cells differentiate into epidermis as their alternate fate when neural differentiation is inhibited. Given that neural fate specification was assessed in totipotent ES cells, and while not wishing to be bound to any particular theorem, it was postulated that three possibilities exist for the acquisition of non-neural cell fates in this model. First, an alternate fate for ES cells under our defined culture conditions may be epidermis, which would indicate that mouse default neuralization is homologous with *Xenopus* default neuralization. Second, any non-neural cell type (including epidermis) may be established in a stochastic manner. Finally, an ES cell phenotype may be maintained in the absence of neural differentiation. These latter two possibilities would indicate that mouse default neuralization may be analogous, but not homologous, to *Xenopus* default neuralization. Again, while not wishing to be bound to any one theory, the results (Figure 5) are consistent with the third possibility; the alternative to neural default for mouse ES cells may be to maintain the undifferentiated ES cell fate. When cell density is increased in the 24 hour differentiation paradigm, the proportion of nuclear Oct-4 expressing ES cells increased, compared to the decrease in β III-tubulin expressing

neurons. Thus, although the establishment of a neural phenotype may be under inhibitory control (a default mechanism), additional signals may be required to drive ES cell differentiation into various non-neural lineages – signals that are likely to be absent or below threshold in the present culture conditions.

Recent evidence suggests that under the influence of a stromal cell line, ES cells can respond to neural inhibitors (in this case BMP4) by differentiating into epidermal cells (Kawasaki et al., 2000). These data suggest that the influence of the stromal cell line may facilitate ectodermal commitment in ES cells, which will then allow these cells to respond to neural inhibitors in a manner that is identical to amphibian ectodermal cells. Therefore, the alternative to a default neural cell fate may be dependent on the degree of commitment toward a particular lineage.

Both LIF and FGF are required for the initial transition of ES cells into neural colony forming stem cells. This raises the question of whether the functions of LIF and FGF are to induce neural stem cell differentiation of ES cells, which would not support the notion of neural fate being achieved autonomously. Although LIF and FGF are required for neural colony formation, the majority of ES cells can take on a neural identity within 24 hours in culture in the absence of any exogenous growth factors. Furthermore, the influence of *Smad4* inactivation on neuronal differentiation (at relatively high densities) indicates that simply attenuating TGF β -related signaling can promote neural specification under relatively inhibitory (high-density) conditions. Finally, preliminary experiments reveal that blocking extracellular FGF signaling using anti-FGF2 antibodies in relatively low cell density cultures does not appreciably decrease the percentage of nestin-expressing cells after 24 hours of differentiation in the absence of LIF. While not wishing to be bound by any one theory, the hypothesis that LIF and FGF (specifically FGF2) are acting permissively to specify a neural fate is supported by the results of targeted null mutations. For instance, the formation of neural tissue and subsequent early neural morphogenesis is relatively

normal in mice lacking the LIF receptor (LIFR) (Li et al., 1995). Moreover, in the *FGFR1* null mice (the primary receptor for FGF2), early gastrulation and neural tube formation was relatively normal (Yamaguchi et al., 1994). However, evidence for neural stem cell proliferation deficits in *FGFR1*^(-/-) mice (Tropepe et al., 1999) as well as motor neuron differentiation deficits in *LIFR*^(-/-) mice (Li et al., 1995) indicate that these factors are important for neural development at slightly later stages. Thus, again, not wishing to be bound by any one theory, we speculate that the primary roles for FGF and LIF are permissive ones and that ES cells autonomously adopt a neural cell fate. Our non-binding proposition is that LIF may initially maintain ES cell survival in these minimal culture conditions, whereas FGF may act primarily as a mitogen for neural stem and progenitor cell proliferation.

In contrast to the ICM and subsequent epiblast cells, ES cells can express the neural precursor marker nestin and the early neuronal marker β III-tubulin within 24 hours when dispersed in culture in the absence of exogenous factors. The onset of nestin expression in vivo occurs at approximately E7.5 within the neuroepithelium of the presumptive neural plate (Lendahl et al., 1990) and neuronal differentiation begins thereafter. One possibility, which is merely a theory to which we do not wish to be bound, that emerges from our findings is that the potential for cells within the ICM or epiblast to behave like primitive neural stem cells in vivo is actively suppressed. For example, epiblast cells in vivo may be competent to differentiate into neurons, but the absence of neurons prior to neurulation (even after a neural fate has been specified) suggests these cells may be inhibited from precocious neuronal differentiation. One intriguing non-binding theory is that the Notch signaling pathway may partially prevent neuronal differentiation by maintaining newly generated neural stem cells in an undifferentiated state. For example, functional inactivation of the mouse *Su(H)/RBP-Jk* gene, a downstream intracellular target of multiple Notch receptors, results in premature neuronal differentiation within the neural plate (de la Pompa et al., 1997). Similarly, functional inactivation of the

mouse bHLH transcription factor *HES1*, which negatively regulates neuronal differentiation via Notch activation, resulted in diminished forebrain neural stem cell self-renewal and a concomitant increase in neuronal differentiation (Nakamura et al., 2000).

5 Studies aimed at testing the role of BMP inhibition in neural fate specification using avian epiblast cells have come to different conclusions. BMP inhibition (by noggin or chordin) was not sufficient for ectopic neural cell differentiation in extraembryonic tissue (Streit et al., 1998; Streit and Stern, 1999), and dissociated epiblast cells
10 preferentially adopted a muscle cell phenotype in culture (George-Weinstein et al., 1996). Combinations of multiple BMP inhibitors, or BMP/Wnt inhibitors may be required for avian neural differentiation to occur. Both BMP and Wnt inhibition causes a more complete secondary axis to form in *Xenopus* transplantation
15 experiments (Glinka et al., 1997). In addition, the generation of mice harboring targeted null mutations in both *Noggin* and *Chordin*, indicate that these two BMP inhibitors may function in concert to exert their effects on neural inhibition during mouse development (Bachiller et al., 2000). In the present study, mCer-1 (known to antagonize BMP, nodal
20 and Wnt signaling) (Piccolo et al., 1999) was similarly effective at augmenting neural stem cell colony formation when compared to Noggin, suggesting that Wnt signaling alone may not actively suppress the ES to neural transition.

 Cell density and culture media conditions employed in some
25 chick studies (George-Weinstein et al., 1996) indicate that the results may in fact be consistent with the neural default model. Although the epiblast cells were cultured at relatively low cell densities (~15 cells/ μ l), they were pre-treated at high cell densities (~400 cells/ μ l) for up to 5 hours in the presence of serum and chick embryo extract
30 (George-Weinstein et al., 1996) a condition likely to suppress neural cell differentiation. Interestingly, these authors reported that neurofilament-expressing chick neurons, when present, were found in relatively cell-dispersed regions of the cultures, whereas muscle cells

were typically aggregated. Thus, these data provide clear examples of how neural differentiation can be inhibited in epiblast cells upon aggregation.

A primitive stage in the neural stem cell lineage

5 The ontogenesis of tissue-specific mammalian stem cells is not well understood. In the present study we identified a novel cell type in the neural lineage based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. This cell type may be suitably
10 described as a primitive neural stem cell. This term has been used previously to describe a stem cell that is primarily tissue-specific, but that retains a certain degree of pluripotency during a restricted early period of development (Morrison et al., 1997).

 With the exception of the hematopoietic stem cell (Weissman,
15 2000), our knowledge of the ontogeny of stem cells in other mammalian organ systems is comparatively limited. Clonal neural colonies generated from ES cells share similar features to clonal neural stem cell colonies described from the embryonic forebrain germinal zone. At a very low frequency (~0.2%), single ES cells proliferate in a LIF- and
20 FGF-dependent manner to form neural colonies that express multiple neural precursor markers (e.g. nestin, *Emx2*, *Hoxb1*), even though the vast majority of ES cells up-regulate nestin expression and down-regulate nuclear Oct-4 expression within 24 hours. We previously demonstrated that the proportion of FGF-dependent neural stem cells
25 isolated from nestin-expressing precursors of the E8.5 anterior neural plate was similar (~0.3%) (Tropepe et al., 1999), and forebrain neural stem cell colonies express similar region-specific patterning genes (present study). Thus, the mechanism for segregating a subpopulation of colony-forming neural stem cells among a larger population of neural
30 cells may be recapitulated during neural fate specification from ES cells. This raises the question of whether the first neural cell to arise in the nervous system is a neural stem cell or whether the first neural derivative is a general neural precursor cell that precedes (or is

generated simultaneously with) the emergence of the neural stem cell lineage (van der Kooy and Weiss, 2000).

5 The ES cell-derived colonies are typically spheroid in morphology and many float in suspension as has previously been described for neural stem cell-derived colonies at all ages (Reynolds and Weiss, 1996). ES cell-derived colonies do not retain ES cell characteristics (e.g. do not express *Brachyury* or Oct-4 protein), but are specified to a neural identity, retaining the expression of neural genes such as *Emx2* and *HoxB1*. Furthermore, cells derived from the neural colonies can
10 differentiate into neurons and glia, suggesting that the initial colony-forming cell had neural multilineage potential. However, neural stem cells derived from ES cells display other features than those derived from the embryonic forebrain, which may indicate an earlier primitive stage in the neural lineage.

15 First, LIF and FGF are critical for ES-derived neural stem cell colony formation and subsequent subcloning (stem cell self-renewal). This is in contrast to neural stem cells isolated from embryonic or adult tissues, where either exogenous FGF or EGF is sufficient for colony formation and subcloning (Reynolds et al., 1992; Reynolds and Weiss,
20 1992). The nature of the LIF effect on the ES to neural transition is not completely understood. Although CNTF can substitute for LIF in maintaining ES cells in an undifferentiated state (Conover et al., 1993; Nichols et al., 1994), it does not substitute for LIF in promoting neural colony formation from ES cells, and LIF alone can not elicit neural
25 colony formation from embryonic derived tissue. Thus, LIF does not appear to maintain neural colonies in an undifferentiated ES state or act as a mitogen. Instead, LIF may act as a survival factor (reviewed in Mehler and Kessler, 1997) that is initially required for ES cell viability. Subsequently, LIF can facilitate colony formation from early embryonic
30 neural stem cells (presumably by keeping more stem cells alive longer), but it is not absolutely required. Hence, growth factor requirements may be sequentially modified from a primitive neural stem cell stage (LIF- and FGF-dependent) to an early embryonic neural stem

cell stage (only FGF-dependent), and finally to a relatively mature neural stem cell stage where both FGF- and EGF-dependent subpopulations co-exist from late embryogenesis into adulthood (Figure 7). A similar role has been attributed to LIF with respect to the survival of primordial germ cells in cultures. Congruent with our results, CNTF was not able to substitute for LIF in keeping primordial germ cells alive, even though embryonic germ cells (an ES-like cell derived from primordial germ cells) could be propagated with several members of the LIF family of ligands, including CNTF (Koshimizu et al., 1996). However, further studies will be required to determine more precisely the factors that mediate the transition from a LIF- and FGF-dependent primitive neural stem cell to a definitive FGF-dependent neural stem cell that can give rise to EGF-dependent stem cells at later embryonic ages.

Second, the expression of neural genes and at least one non-neural gene (GATA4) indicates that the neural stem cell giving rise to neural colonies may retain a certain degree of pluripotency or primitive characteristics. Most important, this retained pluripotency can be observed in the ability of sphere colony derived cells to extensively colonize various embryonic tissues under appropriate influences in the chimeric embryos in vivo (no such pluripotency is shown by neural tube derived neural stem cells under similar conditions). Under the culture conditions employed in the present study the colony-forming neural stem cells derived from ES cells are specified, but not committed, to a neural fate.

Therefore, it has been identified a novel cell type in the neural lineage based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. This cell type may be suitably described as a primitive neural stem cell or a pre-neural stem cell, a term that has been used by others (Morrison et al., 1997) to describe a stem cell that is primarily tissue-specific, but that retains a certain degree of pluripotency during a restricted early period of development.

Lineage restriction in developing neural stem cells may be reversible

To what extent can the microenvironment dictate the identity of neural stem cells and their ability to produce different progeny? We demonstrate that ES-derived primitive neural stem cells can produce progeny that colonize neural and non-neural tissues in chimeric mice in vivo. In contrast, we were unable to generate chimeras using neural stem cell colonies derived from either the early embryonic or adult forebrain. While not wishing to be bound to any one theory, this difference would suggest that primitive neural stem cells transiently retain their pluripotency, but through development neural stem cells become restricted in their ability to generate non-neural cell types. This restriction, however, may be reversible.

Clarke et al. (2000) recently demonstrated that a very low percentage (6 chimeras out of 600 viable embryos, or 1%) of adult neural stem cell colony cells could contribute to neural and non-neural tissues in a mouse chimera paradigm similar to the one we utilized in the present study. An increase in the frequency of chimeras was observed when undissociated stem cell colonies were injected into the mouse blastocoel or chick amniotic cavity (Clarke et al., 2000). Consistent with our findings, the degree to which definitive neural stem cell-derived progeny (after isolation from embryonic or adult brain) can contribute to non-neural tissue in mouse is very restricted, compared to the proportion of ES cell derived primitive neural stem cell progeny that contribute to neural and non-neural tissues in the present study (22 chimeras out of 24 viable embryos, or 92%). However, it is clear from their analysis of the inductive influence of EB on adult neural stem cell colonies in vitro (to form muscle cells), that appropriate inductive signals can reveal some potential of neural stem cells to give rise to non-neural cells independent of the in vivo environment (Clarke et al., 2000). One intriguing possibility is that these inductive cues could enable some of the definitive neural stem cells to revert to a pluripotent primitive neural stem cell stage and subsequently produce progeny indicative of all three germ layers. Thus, the delineation of a pluripotent primitive neural stem cell stage during neural stem cell ontogeny may

provide a basis for further understanding the mechanisms governing this remarkable cellular plasticity.

An ES cell paradigm for neural stem cell fate specification

Several studies have demonstrated neural differentiation from EB
5 derived cells, with the addition of specific growth factors (Doetschman et al., 1985; Bain et al., 1995; Fraichad et al., 1995; Strubing et al., 1995; Okabe et al., 1996; Brustle et al., 1999). Also, BMP4 has been shown to suppress neuronal differentiation of EB derived cells (Finley et al., 1999). Although these observations clearly demonstrate the potency of
10 such factors to promote or attenuate neuronal differentiation, each experiment initially utilized EB cultures in the presence of serum. Here we present an alternative and specific paradigm for neural cell fate specification directly from ES cells in serum-free conditions in the absence of EB formation. This paradigm can facilitate, for instance, the
15 discovery of genes that positively and negatively regulate the transition from an ES cell to a neural cell by utilizing an expression-based gene trap library of ES cell lines (Stanford et al., 1998; Seaberg et al., 1999). Thus, our present findings underscore the potential for using ES cell models of mammalian neural development.

20 While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the
25 appended claims.

All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

- 5 Acampora, D., Avantaggiato, V., Tuorto, F., Briata, P., Corte, G., Simeone, A. (1998). Visceral endoderm-restricted translation of Otx1 mediates recovering of Otx2 requirements for specification of anterior neural plate and proper gastrulation. *Development* 125, 5091-5104.
- 10 Arceci, R.J., King, A.A.J., Simon, M.C., Orkin, S.H., Wilson, D.B. (1993). Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart. *Mol. Cell. Biol.* 13, 2235-2246.
- Bachiller, D., Klingensmith, J., Kemp, C., Belo, J.A., Anderson, R.M., May, S.R., McMahon, J.A., McMahon, A.P., Harland, R.M., Rossant, J., De Robertis, E.M. (2000). The organizer factors chordin and noggin are required for mouse forebrain development. *Nature* 403, 658-661.
- 15 Bain, G., Kitchens, D., Yao, M., Huettner, J.E., Gottlieb, D.I. (1995). Embryonic stem cells express neuronal properties in vitro. *Dev. Biol.* 168, 342-357.
- Beddington, R.S. (1994). Induction of a second neural axis by the node. *Development* 120, 613-620.
- 20 Beddington, R.S.P., Robertson, E.J. (1989). An assessment of the developmental potential of embryonic stem cells in the midgestation mouse embryo. *Development* 105, 733-737.
- Beddington, R.S.P., Rashbass, P., Wilson, V. (1992). Brachyury – a gene affecting mouse gastrulation and early organogenesis. *Development Supplement*, 157-165.
- 25 Beddington, R.S.P., Robertson, E.J. (1999). Axis development and early asymmetry in mammals. *Cell* 96, 195-209.
- Bellows, C.G., Aubin, J.E. (1989). Determination of numbers of osteoprogenitors present in isolated fetal rat calvaria cells in vitro. *Dev. Biol.* 133, 8-13.
- 30 Belo, J.A., Bouwmeester, T., Leyns, T., Kertesz, L., Gallo, N., Follettie, M., De Robertis, E.M. (1997). Cerberus-like is a secreted factor with neuralizing activity expressed in the anterior primitive endoderm of the mouse gastrula. *Mech. Dev.* 68, 45-57.
- 35 Bouwmeester, T., Kim, S.H., Sasai, Y., Lu, B., De Robertis, E.M. (1996). Cerberus is a head inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. *Nature* 382, 595-601.

- Brustle, O., Jones, K.N., Learish, R.D., Karram, K., Choudhary, K., Wiestler, O.D., Duncan, I.D., McKay, R.D.G. (1999). Embryonic stem cell-derived glial precursors: a source of myelinating transplants. *Science* 285, 754-756.
- 5 Chiasson, B.J., Tropepe, V., Morshead, C.M., van der Kooy, D. (1999). Adult mammalian forebrain ependymal and subependymal cells demonstrate proliferative potential, but only subependymal cells have neural stem cell characteristics. *J. Neurosci.* 19, 4462-4471.
- 10 Ciruna, B.G., Schwartz, L., Harpal, K., Yamaguchi, T.P., Rossant, J. (1997). Chimeric analysis of fibroblast growth factor receptor-1 (Fgfr-1) function: a role for FGFR1 in morphogenetic movement through the primitive streak. *Development* 124, 2829-2841.
- 15 Clarke, D.L., Johansson, C.B., Wilbertz, J., Veress, B., Nilsson, E., Karlstrom, H., Lendahl, U., Frisen, J. (2000). Generalized potential of adult neural stem cells. *Science* 288, 1660-1663.
- 20 Conover, J.C., Ip, N.Y., Poueymirou, W.T., Bates, B., Goldfarb, M.P., DeChiara, T.M., Yancopoulos, G.D. (1993). Ciliary neurotrophic factor maintains the pluripotentiality of embryonic stem cells. *Development* 119, 559-565.
- 25 Coucouvanis, E., Martin, G.R. (1995). Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. *Cell* 83, 279-287.
- 30 Coucouvanis, E., Martin, G.R. (1999). BMP signaling plays a role in visceral endoderm differentiation and cavitation in the early mouse embryo. *Development* 126, 535-546.
- 35 Dani, D., Chambers, I., Johnstone, S., Robertson, M., Ebrahimi, B., Saito, M., Taga, T., Li, M., Burdon, T., Nichols, J., Smith, A. (1998). Paracrine induction of stem cell renewal by LIF-deficient cells: a new ES cell regulatory pathway. *Dev. Biol.* 203, 149-162.
- 40 de la Pompa, J.L., Wakeman, A., Correia, K.M., Samper, E., Brown, S., Aguilera, R.J., Nakano, T., Honjo, T., Mak, T.W., Rossant, J., Conlon, R.A. (1997). Conservation of the Notch signaling pathway in mammalian neurogenesis. *Development* 124, 1139-1148.
- 45 Doetschman, T.C., Eistetter, H., Katz, M., Schmidt, W., Kemler, R. (1985). The in vitro development of blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands, and myocardium. *J. Embryol. Exp. Morphol.* 87, 27-45.
- 50 Elefanty, A.G., Robb, L., Birner, R., Begley, C.G. (1997). Hematopoietic-specific genes are not induced during in vitro

- differentiation of scl-null embryonic stem cells. *Blood* 90, 1435-1447.
- Evans, M.J., Kaufman, M.H. (1981). Establishment in culture of pluripotential cells from mouse embryos. *Nature* 292, 154-156.
- 5 Fainsod, A., Deisler, K., Yelin, R., marom, K., Epstein, M., Pillemer, G., Steinbeisser, H., Blum, M. (1997). The dorsalizing and neural inducing gene follistatin is an antagonist of BMP-4. *Mech. Dev.* 63, 39-50.
- Finley, M.F.A., Devata, S., Huettnner, J.E. (1999). BMP-4 inhibits neural differentiation of murine embryonic stem cells. *J. Neurobiol.* 40, 271-287.
- 10 Friedrich, G., Soriano, P. (1991). Promotor traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice. *Genes Dev.* 5, 1513-1523.
- 15 Fraichard, A., Chassande, O., Bilbaut, G., Dehay, C., Savatier, P., Samarut, J. (1995). In vitro differentiation of embryonic stem cells into glial cells and functional neurons. *J. Cell Sci.* 108, 3181-3188.
- George-Weinstein, M., Gerhart, J., Reed, R., Flynn, J., Callihan, B., Mattiacci, M., Miehle, C., Foti, G., Lash, J.W., Weintraub, H. (1996). Skeletal myogenesis: the preferred pathway of chick embryo epiblast cells in vitro. *Dev. Biol.* 173, 279-291.
- 20 Glinka, A., Wu, W., Onichtchouk, D., Blumenstock, C., Niehrs, C. (1997). Head induction by simultaneous repression of Bmp and Wnt signalling in *Xenopus*. *Nature* 389, 517-519.
- Godsave, S.F., Slack, J.M.W. (1989). Clonal analysis of mesoderm induction in *Xenopus laevis*. *Dev. Biol.* 134, 486-490.
- 25 Grinblat, Y., Gamse, J., Patel, M., Sive, H. (1998). Determination of the zebrafish forebrain: induction and patterning. *Development* 125, 4403-4416.
- 30 Grunz, H., Tacke, L. (1989). Neural differentiation of *Xenopus laevis* ectoderm takes place after disaggregation and delayed reaggregation without inducer. *Cell Differ. Dev.* 28, 211-218.
- Hadjantonakis, A.K., Gertsenstein, M., Ikawa, M., Okabe, M., Nagy, A. (1998). Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76, 79-90.
- 35 Harland, R., Gerhart, J. (1997). Formation and function of Spemann's organizer. *Annu. Rev. Cell Dev. Biol.* 13, 611-667.
- Hemmati-Brivanlou, A., Melton, D.A. (1992). A truncated activin receptor

inhibits mesoderm induction and formation of axial structures in *Xenopus* embryos. *Nature* 359, 609-614.

Hemmati-Brivanlou, A., Melton, D.A. (1994). Inhibition of activin receptor signaling promotes neuralization in *Xenopus*. *Cell* 77, 273-281.

- 5 Hemmati-Brivanlou, A., Melton, D.A (1997). Vertebrate neural induction. *Annu. Rev. Neurosci.* 20, 43-60.

Hoodless, P.A., Hemmati-Brivanlou, A. (1997). Inhibitory control of neural differentiation in mammalian cells. *Dev. Genes Evol.* 297, 19-28.

- 10 Hoppler, S., Brown, J.D., Moon, R.T. (1996). Expression of a dominant-negative Wnt blocks induction of MyoD in *Xenopus* embryos. *Genes Dev.* 10, 2805-2817.

Johansson, B.M., Wiles, M.V. (1995). Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. *Mol. Cell Biol.* 15, 141-151.

- 15 Kawasaki, H., Mizuseki, K., Nishikawa, S., Kaneko, S., Kuwana, Y., Nakanishi, S., Nishikawa, S.-I., Sasai, Y. (2000). Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. *Neuron* 28, 31-40.

- 20 Kishimoto, T., Taga, T., Akira, S. (1994). Cytokine signal transduction. *Cell* 76, 253-

- 25 Koshimizu, U., Taga, T., Watanabe, M., Saito, M., Shirayoshi, Y., Kishimoto, T., Nakatsuji, N. (1996). Functional requirement of gp130-mediated signaling for growth and survival of mouse primordial germ cells in vitro and derivation of embryonic germ (EG) cells. *Development* 122, 1235-1242.

Lamb, T.M., Knecht, A.K., Smith, W.C., Stachel, S.E., Economides, A.N., Stahl, N., Yancopoulos, G.D. (1993). Neural induction by the secreted polypeptide noggin. *Science* 262, 713-718.

- 30 Lendahl, U., Zimmerman, L.B., McKay, R.D.G. (1990). CNS stem cells express a new class of intermediate filament protein. *Cell* 60, 585-595.

Li, M., Sendtner, M., Smith, A. (1995). Essential function of LIF receptor in motor neurons. *Nature* 378, 724-727.

- 35 Li, J., Ning, G., Duncan, S.A. (2000). Mammalian hepatocyte differentiation requires the transcription factor HNF4. *Genes Dev.* 14, 464-474.

Martens, D.J., Tropepe, V., van der Kooy, D. (2000). Separate

- proliferation kinetics of fibroblast growth factor-responsive and epidermal growth factor-responsive neural stem cells within the embryonic forebrain germinal zone. *J. Neurosci.* 20, 1085-1095.
- 5 Martin, G.R., Wiley, L.M., Damjanov, I. (1977). The development of cystic embryoid bodies in vitro from clonal teratocarcinoma stem cells. *Dev. Biol.* 61, 230-244.
- Martin, G.R. (1981). Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc. Natl. Acad. Sci. USA* 78, 7634-7638.
- 10 McGowan, K.M., Coulombe, P.A. (1998). Onset of keratin 17 expression coincides with the definition of major epithelial lineages during skin development. *J. Cell Biol.* 143, 469-486.
- Mehler, M.F., Kessler, J.A. (1997). Hematolymphopoietic and inflammatory cytokines in neural development. *Trends in Neurosci.* 20, 357-365.
- 15 Mokry, J., Nemecek, S. (1998). Immunohistochemical detection of intermediate filament nestin. *Actin Medica (Hradec Kralove)* 41, 73-80.
- Morrison, S.J., Shah, N.M., Anderson, D.J. (1997). Regulatory mechanisms in stem cell biology. *Cell* 88, 287-298.
- 20 Nagy, A., Rossant, J. (1993). Production of a complete ES cell derived fetus. In *Gene targeting: a practical approach* (ed. A.L. Joyner), pp. 147-179. IRL Press, Oxford, UK.
- Nakamura, Y., Sakakibara, S-I., Miyata, T., Ogawa, M., Shimazaki, T., Weiss, S., Kageyama, R., Okano, H. (2000). The bHLH gene *HES1* is a repressor of the neuronal commitment of CNS stem cells. *J. Neurosci.* 20, 283-293.
- 25 Nichols, J., Chambers, I., Smith, A. (1994). Derivation of germline competent embryonic stem cells with combination of interleukin-6 and soluble interleukin-6 receptor. *Exp. Cell Res.* 215, 237-239.
- 30 Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., Chambers, I., Schoeler, H., Smith, A. (1998). Formation of pluripotential stem cells in the mammalian embryo depends on the POU transcription factor Oct4. *Cell* 95, 379-391.
- 35 Okabe, S., Forssberg-Nilsson, K., Spiro, A.C., Segal, M., McKay, R.D.G. (1996). Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro. *Mech. Dev.* 59, 89-102.

- Oliver, G., Mailhos, A., Wehr, R., Copeland, N.G., Jenkins, N.A., Gruss, P. (1995). *Six3*, a murine homologue of the *sine oculis* gene, demarcates the most anterior border of the developing neural plate and is expressed during eye development. *Development* 121, 4045-4055.
- 5 Oppenheimer, J.M. (1936). Structures developed in amphibians by implantation of living fish organizer. *Proc. Soc. Exp. Biol. Med.* 34, 461-463.
- O'Shea, K.S. (1999). Embryonic stem cell models of development. *Anat. Rec. (New Anat.)* 257, 32-41.
- 10 Pearce, J.J.H., Penny, G., Rossant, J. (1999). A mouse cerberus/DAN-related gene family. *Dev. Biol.* 209, 98-110.
- Piccolo, S., Sasai, Y., Lu, B., De Robertis, E.M. (1996). Dorsoventral patterning in *Xenopus*: inhibition of ventral signals by direct binding of chordin to BMP4. *Cell* 86, 589-598.
- 15 Piccolo, S., Agius, E., Leyns, L., Bhattacharyya, S., Grunz, H., Bouwmeester, T., De Robertis, E.M. (1999). The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. *Nature* 397, 707-710.
- 20 Potten, C.S., Loeffler, M. (1990). Stem cells: attributes, cycles, spirals, pitfalls and uncertainties. Lessons for and from the crypt. *Development* 110, 1001-1020.
- Reynolds, B.A., Tetzlaff, W., Weiss, S. (1992). A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. *J. Neurosci.* 12, 4565-4574.
- 25 Reynolds, B.A., Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science* 255, 1707-1710.
- Reynolds, B.A., Weiss, S. (1996). Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. *Dev. Biol.* 175, 1-13.
- 30 Sasai, Y., Lu, B., Steinbeisser, H., De Robertis, E.M. (1995). Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in *Xenopus*. *Nature* 376, 333-336.
- 35 Sato, S.M., Sargent, T.D. (1989). Development of neural inducing capacity in dissociated *Xenopus* embryos. *Dev. Biol.* 134, 263-266.
- Seaberg, R.M., Tropepe, V., Stanford, W.L., Bernstein, A., van der Kooy, D. (1999). Neural determination genes revealed by expression trapping

- 57 -

in embryonic stem cells. Soc. Neurosci. Abst. 25, 527.

- 5 Simeone, A., Gulisano, M., Acampora, D., Stornaiuolo, A., Rambaldi, M., Boncinelli, E. (1992). Two vertebrate homeobox genes related to the *Drosophila empty spiracles* gene are expressed in the embryonic cerebral cortex. EMBO J. 11, 2541-2550.
- Simeone, A., Acampora, D., Gulisano, M., Stornaiuolo, A., Boncinelli, E. (1992). Nested expression domains of four homeobox genes in developing rostral brain. Nature 358, 687-690.
- 10 Sirard, C., De la Pompa, J.L., Elia, A.J., Itie, A., Mirtsos, C., Cheung, A., Hahn, S., Wakeham, A., Schwartz, L., Kern, S.E., Rossant, J., Mak, T.W. (1998). The tumor suppressor gene *Smad4/Dpc4* is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev. 12, 107-119.
- 15 Smith, A.G., Heath, J.K., Donaldson, D.D., Wong, G.G., Moreau, J., Stahl, M., Rogers, D. (1988). Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. Nature 336, 688-690.
- Smith, W.C., Knecht, A.K., Wu, M., Harland, R.M. (1993). Secreted noggin protein mimics the Spemann organizer in dorsalizing *Xenopus* mesoderm. Nature 361, 547-549.
- 20 Solter, D., Knowles, B.B. (1978). Monoclonal antibody defining a stage-specific mouse embryonic antigen (SSEA-1). Proc. Natl. Acad. Sci. USA 75, 555-5569.
- 25 Spemann, H., Mangold, H. (1924). Über induktion von embryonalanlagen durch implantation artfremder organisatoren. Arch. Mikr. Anat. EntwMech. 100, 599-638.
- Stanford, W.L., Caruana, G., Vallis, K.A., Inamdar, M., Hidaka, M., Bautch, V.L., Bernstein, A. (1998). Expression trapping: Identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Blood 92, 4622-4631.
- 30 Streit, A., Lee, K.J., Woo, I., Roberts, C., Jessell, T.M., Stern, C.D. (1998). Chordin regulates primitive streak development and the stability of induced neural cells, but is not sufficient for neural induction in the chick embryo. Development 125, 507-519.
- 35 Streit, A., Stern, C.D. (1999). Neural induction: a bird's eye view. Trends in Genet. 15, 20-24.
- Strubing, C., Ahnert-Hilger, G., Shan, J., Wiedenmann, B., Hescheler, J., Wobus, A.M. (1995). Differentiation of pluripotent embryonic stem cells into the neuronal lineage in vitro gives rise to mature inhibitory and

- excitatory neurons. *Mech. Dev.* 53, 275-287.
- 5 Taraviras, S., Monaghan, A.P., Schutz, G., Kelsey, G. (1994). Characterization of the mouse HNF-4 gene and its expression during mouse embryogenesis. *Mech. Dev.* 48, 67-79.
- Tohyama, T., Lee, L.M.-Y., Rorke, L.B., Marvin, M., McKay, R.D.G., Trojanowski, J.Q. (1992). Nestin expression in embryonic human neuroepithelial tumor cells. *Lab. Invest.* 66, 303-313.
- 10 Tropepe, V., Sibilia, M., Ciruna, B.G., Rossant, J., Wagner, E.F., van der Kooy, D. (1999). Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. *Dev. Biol.* 208, 166-188.
- van der Kooy, D., Weiss, S. (2000). Why stem cells? *Science* 287, 1439-1441.
- 15 Waddington, C.H., Schmidt, C.A. (1933). Induction by heteroplastic grafts of the primitive streak in birds. *Roux's Arch. EntwMech. Org.* 128, 522-563.
- Weissman, I.L. (2000). Stem cells: units of development, units of regeneration and units of evolution. *Cell* 100, 157-168.
- 20 Wiles, M.V., Johansson, B.M. (1997). Analysis of factors controlling primary germ layer formation and early hematopoiesis using embryonic stem cell in vitro differentiation. *Leukemia* 11(S3), 454-456.
- Wilkinson, D.G., Bhatt, S., Cook, M., Boncinelli, E., Krumlauf, R. (1989). Segmental expression of Hox-2 homeobox-containing genes in the developing mouse hindbrain. *Nature* 341, 405-409.
- 25 Williams, R.L., Hilton, D.J., Pease, S., Willson, T.A., Stewart, C.L., Gearing, D.P., Wagner, E.F., Metcalf, D., Nicola, N.A., Gough, N.M. (1988). Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature* 336, 684-687.
- 30 Wilson, P.A., Hemmati-Brivanlou, A. (1995). Induction of epidermis and inhibition of neural fate by Bmp-4. *Nature* 376, 331-333.
- Wilson, P.A., Lagna, G., Suzuki, A., Hemmati-Brivanlou, A. (1997). Concentration-dependent patterning of the *Xenopus* ectoderm by BMP4 and its signal transducer Smad1. *Development* 124, 3177-3184.
- 35 Wrana, J.L. (2000). Regulation of Smad activity. *Cell* 100, 189-192.
- Yamaguchi, T.P., Harpal, K., Henkemeyer, M., Rossant, J. (1994). *fgfr-1* is required for embryonic growth and mesodermal patterning during

- 59 -

mouse gastrulation. Genes Dev. 8, 3032-3044.

Zimmerman, L.B., De Jesus-Escobar, J.M., Harland, R.M. (1996). The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86, 599-606.

DETAILED DESCRIPTION OF THE FIGURES

Figure 1. LIF-dependent neural cell colonies are clonally derived from single ES cells. (A) ES cells cultured at 20 cells/ μ l in chemically defined serum-free media proliferate to form sphere colonies in the presence of LIF (1000 U/ml). Photo inset shows a ES derived sphere colony after 7 days in culture (scale bar 100 μ m). The addition of FGF2 (10 ng/ml) and heparin (2 (g/ml) causes a slight, but non-significant increase in the numbers of primary sphere colonies compared to LIF alone ($t = 1.1$, $p > 0.05$) or LIF+B27 ($t = 1.2$, $p > 0.05$). The presence of FGF2+heparin alone or B27 supplement alone (diluted to one-tenth the stock concentration: 1X) is not sufficient for colony formation. Data represent 6-12 cultures per group from 4-11 separate experiments. (B) Cells plated at limiting dilution in the presence of LIF revealed that the frequency in which at least one neural stem cell will proliferate to form a sphere colony (37% mark on the ordinal scale) was $\sim 0.2\%$ (dashed line). Each data point represents the average of 6 cultures from 2 separate experiments. (C) Sphere colonies are composed of cells with neural precursor identity. After 3 days in vitro (relatively small) or 7 days in vitro (relatively large) individual sphere colonies ($n=6$ from each of 2 separate experiments) were transferred to a poly-ornithine substrate and allowed to adhere for 24 hours. The expression of the neural precursor marker nestin was determined using immunocytochemistry. Scale bar 100 μ m. (D) Neural colony forming ES cells displayed neural stem cell self-renewal characteristics. Single primary colonies generated in the presence of LIF alone (1a) were subcloned in LIF+FGF2, FGF2 or LIF to generate secondary colonies. Single primary colonies generated in the presence of LIF+FGF2+B27 (1b) were subcloned in LIF+FGF2+B27, FGF2+B27 or LIF+B27 to generate secondary colonies. Single secondary colonies generated in LIF+FGF2+B27 (2) were subcloned in LIF+FGF2+B27 to generate tertiary colonies. Single tertiary colonies generated in LIF+FGF2+B27 (3) were subcloned in LIF+FGF2+B27 to generate quaternary colonies.

- 61 -

Single sphere colonies from primary culture (n=6-24 isolated colonies per condition from at least 2 separate experiments) were dissociated into a single cell suspension after 7 days in vitro and re-cultured. Secondary colonies derived from single primary colonies were
 5 quantified after 7-10 days in vitro and a similar procedure was used to subclone secondary and tertiary sphere colonies. LIF (1000 U/ml), FGF2 (10 ng/ml), heparin (2 µg/ml), B27 supplement (1X).

Figure 2. Cells from ES-derived sphere colonies express neural-specific genes and differentiate into neurons and glia. (A) Differentiated
 10 ES sphere colonies contain neurons (MAP2+), astrocytes (GFAP+) and oligodendrocytes (O4+, arrowhead). Data are representative of 18 cultures from 2-3 separate experiments. (B) Gene expression analysis using RT-PCR. RNA was isolated from sphere colonies after 7 days in vitro and analyzed for the expression of markers for neural differentiation
 15 [Emx2 (151 bp), HoxB1 (325 bp), Six3 (571 bp), and Otx1 (128 bp)], endoderm differentiation [GATA4 (809 bp), HNF4 (629 bp)] mesoderm differentiation [Brachyury (857 bp)] and epidermis differentiation [cytokeratin-17 (CK-17) (833 bp)]. To normalize for the amount of cDNA present in the sample, the cDNA for GADPH (401 bp) was amplified. R1
 20 refers to primary ES cells; SC refers to ES-derived sphere colony; + refers to positive tissue control (forebrain, hindbrain, somitic mesoderm, liver, skin). Data are representative of at least 3 separate experiments. Scale bar: 20 mm.

Figure 3. Endogenous FGF-signaling mediates LIF-dependent primary
 25 neural colony formation. (A) Signaling through FGF-receptor-1 is required for neural colony formation. ES cells with a homozygous null mutation in the gene encoding FGF-receptor-1 (*fgfr1Dtmk/fgfr1Dtmk*) or control heterozygous ES cells (*fgfr1Dtmk/+*) were cultured at 20 cells/ml in LIF alone or LIF+FGF2+heparin and sphere colonies (n=12 cultures
 30 per group) were quantified after 7 days in vitro (t = 8.5, p<0.05 comparing mutant and wildtype cells in LIF alone; t = 8.9, p<0.05

- 62 -

comparing mutant and wildtype cells in LIF+FGF2). (B) Anti-FGF2 antibodies block neural colony formation. ES cells were cultured at 20 cells/ml in the presence of LIF or LIF+FGF2+heparin alone or in the presence of 1.25 mg/ml mouse monoclonal IgG anti-FGF2 antibodies.

5 Data represent the average of 6 cultures per group from 2-3 separate experiments ($t = 3.66$, $p < 0.05$ comparing LIF alone in presence or absence of antibody; $t = 2.21$, $p < 0.05$ comparing LIF+FGF2 in presence or absence of antibody). (C) LIF facilitates colony formation in FGF2 from neural stem cells isolated from the E9.5 forebrain vesicles compared to

10 FGF2 alone ($t = 2.9$, $p < 0.05$). Germinal zone tissue was cultured at 10 cells/ml in either FGF2+heparin or in the presence of FGF2+heparin and LIF and colonies were quantified after 7 days in vitro. Data represent the average of 6-9 embryos per group.

Figure 4. TGFb/Wnt signaling can modulate neural stem cell differentiation from ES cells. (A) BMP4 inhibits neural colony formation compared to controls ($t = 4.45$, $p < 0.05$). ES cells were cultured at 20 cells/ml in the presence of LIF+FGF2+heparin alone or in the presence of BMP4. Sphere colonies were quantified after 7 days in vitro. Data represent the average of 6 cultures per group from 2 separate

15 experiments. (B) Under similar conditions, Noggin (100 mg/ml) enhances neural colony formation compared to controls ($t = 4.78$, $p < 0.05$). Sphere colonies were quantified after 7 days in vitro. Data represent the average of 6 cultures per group from 2 separate

20 experiments. (C) A null mutation in the *Smad4* gene enhances neural colony formation compared to wildtype controls ($t = 2.67$, $p < 0.05$). *Smad4*(-/-) and wildtype E14K ES cells were cultured at 20 cells/ml in the presence of LIF and sphere colonies were quantified after 7 days in vitro. Data represent 6-12 cultures per group from 3-5 separate

25 experiments. (D) mCer-I enhances neural colony formation compared to controls ($t = 2.4$, $p < 0.05$). ES cells were cultured at 20 cells/ml in the presence of LIF and B27 in the presence of 20% (v/v) in 0.5 ml culture wells of media supernatant from Neuro2a cell lines transiently

30

expressing a mCer-I transgene or V2 plasmid control. Sphere colonies were quantified after 7 days in vitro. Data represent an average of 6 cultures per group from 2 separate experiments.

Figure 5. Neural cell fate inhibition is attenuated in relatively low cell density cultures. ES cells were cultured on a poly-ornithine substrate for 24 hours at 50 cells/ml or 10 cells/ml in the absence of exogenous growth factors or, where indicated, in the presence of LIF+FGF2+heparin. (A) Cells expressing nestin, bIII-tubulin, NeuN and Oct-4. Cultures were counter-labeled with Hoechst nuclear dye to facilitate cell quantitation. (B) In a similar manner, nestin and bIII-tubulin expression were assessed in *Smad4*(-/-) ES cells, compared to the E14K wildtype controls, plated at 50 cells/ml. Data represent the average proportion of phenotype-specific cells (positively immunolabeled) per total numbers of cells (Hoechst-labeled) obtained from 4-6 random standardized areas (using an ocular grid) at 20X objective magnification from 3-6 separate cultures. Scale bar: 20 mm. n.d., not determined.

Figure 6. ES-derived neural sphere colonies contribute extensively in mouse chimeras. (A) Chimeric E9.5 embryo generated with a YFP ES sphere colony and a CD1 host morula. YFP-expressing cells are evident in all embryonic tissues (large arrow) and yolk sac (small arrow), but are absent from the placenta (outlined with dashed lines). Inset shows a normally developed blastocyst after 24 hours in vitro from the aggregation of a YFP ES sphere colony and a CD1 host morula. YFP cells integrate extensively into the ICM (large arrow), whereas the trophectoderm (faintly illuminated with a low intensity white light) is normally devoid of YFP cells (small arrow). (B) Twenty-four hours after the attempted aggregation of a GFP sphere colony derived from the E9.5 forebrain and a CD1 host morula, the morula develops normally into a blastocyst (arrow), while the sphere colony remains unintegrated outside of the embryo (both visualized with low intensity white light). (C)

- 64 -

GFP-expressing cells were not observed within the embryo. Scale bar: 1 mm (A), 750 mm (A, inset), 250 mm (B, C).

Figure 7. Undifferentiated ES cells do not express nestin at high cell densities. A small proportion of ES cells cultured at high cell densities (~100 cells/ml) on a gelatin substrate in the presence of LIF and 15% FCS display a relatively large flattened morphology and express nestin (arrowheads in A). In phase contrast images, these nestin positive cells are almost exclusively found between clusters of small rounded cells in areas of minimal cell to cell contact (arrowheads in B). The well-circumscribed clusters of cells, which do not express nestin (arrow in A and B) resemble typical undifferentiated ES cell colonies. These aggregated cells express the undifferentiated ES cell-specific marker SSEA-1 (arrowheads in C and D). Moreover, the relatively large cells that resemble nestin-positive cells do not express SSEA-1 (arrow in C and D). (E) A model depicting the establishment of the early neural lineage from ES cells. Totipotent ES cells derived from the E3.5 ICM directly differentiate (limited by the inhibitory control of TGFb molecules) to give rise to LIF- and FGF-dependent pluripotent primitive neural stem cells that undergo relatively few symmetric (expansionary) divisions. These primitive neural stem cells can generate neurons and glia, but under appropriate environmental conditions (chimeric embryos) have the potential to generate cells with the capacity to differentiate into various cell types. As development proceeds, primitive neural stem cells give rise to FGF-dependent (and not LIF-dependent) neural stem cells that are present at the neural plate stage at E8.5 (Tropepe et al., 1999). The FGF-responsive neural stem cells initially undergo mostly asymmetric divisions, but at later stages divide symmetrically to expand their population. By E14.5, FGF-responsive neural stem cells also give rise to a relatively separate EGF-responsive neural stem cell population, both of which have the potential to generate neurons and glia (Tropepe et al., 1999; Martens et al, 2000). Scale bar 40mm.

We claim:

1. A method for differentiating embryonic stem cells to cells with markers characteristic of neural cells comprising:
 - (a) culturing the embryonic stem cells in a serum free media at low cell density wherein said density is selected to minimize ES cell aggregation or EB formation;
 - (b) allowing said cells to differentiate.
2. The method of claim 1 wherein the density is selected as to avoid EB formation.
3. The method of claim 1 wherein said cell density is greater than 0 cells/ μ l to 50 cells/ μ l.
4. The method of claim 3 wherein the cell density is greater than 0 cells/ μ l to 20 cells/ μ l.
5. The method of claim 4 wherein the cell density is greater than 0 cells/ μ l to 10 cells/ μ l.
6. The method of claim 5 wherein the cell density is 10 cells/ μ l.
7. The method of claims 5 wherein there is no EB formation.
8. The method of anyone of claims 7 wherein the differentiating ES cells form at least one neurosphere.
9. The method of claim 1-6 wherein the differentiating ES cells form at least one neurosphere.
10. The method of claim 1-7 wherein the serum free media further comprises a cytokine.

11. The method of claim 10 wherein the cytokine is leukemia inhibitory factor (LIF)
12. The method of claim 11 wherein the ES cells differentiate into a primitive neural stem cell, that is pluripotent.
- 5 13. The method of anyone of claims 1-11 wherein the serum free media further comprises a growth factor.
14. The method of claim 13 wherein the growth factor is selected from the members of the fibroblast growth factor (FGF) family of growth factors.
- 10 15. The method of claim 14 wherein the growth factor is FGF2.
16. The method according to anyone of claims 1-15 wherein the media comprises an inhibitor of TGF- β -related signaling.
17. The method of claim 16, wherein the inhibitor is the protein Noggin.
18. The method of claim 16 wherein the inhibitor is selected from the Cerebus family of proteins.
- 15 19. A method for producing secondary neural stem cell colonies comprising:
- (a) culturing ES cells in low cell density completely defined serum-free media for a time and under conditions sufficient to differentiate the said ES cells;
- 20 (b) dissociating and subcloning primary neural cell colonies generated from the said ES cells; and
- (c) administering a growth factor to the dissociated neural cells.

- 67 -

20. A method according to claim 19 wherein the growth factor is selected from among the members of the fibroblast growth factor (FGF) family of growth factors.
21. A method according to claims 20 wherein the growth factor is FGF2.
22. A method according to claim 19 -21 wherein a cytokine is administered to the dissociated neural cells.
23. A method according to claim 19-22 wherein the cytokine is LIF or B27.
24. One or more cell(s) expressing one or more neural precursor cell marker(s) and/or one or more neural-specific mRNA molecule(s), and having multilineage potential.
25. A cell according to claim 24 wherein the neural precursor marker nestin is expressed.
26. A cell according to claim 24 or 25 wherein the neural-specific mRNA molecule is Emx2 or HoxB1.
27. A method according to anyone of claims 1-11 for analyzing the role of genes in the regulation of neural fate specification.
28. A primitive neural stem cell produced by the method of claims 1 -11 that comprises neural cell markers and is pluripotent.
29. A LIF dependent primitive neural stem cell comprising at least one neural cell marker and that is pluripotent.
30. A method of producing a pre-selected cell type derived from a cell of

- 68 -

claim 25, 26, 28 or 29 comprising, culturing the cells under differentiating conditions that promote formation of the cell type.

31. The method of claim 30 wherein the pre-selected cell type is a neural cell, and the differentiating conditions comprise culturing the cell
5 in a serum free media that comprises FGF2.

32. A method for screening for modulators of cellular differentiation comprising:

- (a) culturing pluripotent cells in serum-free media under low density conditions in the presence of the potential modulator;
- 10 (b) allowing for differentiation of the cells;
- (c) detecting any differentiation of the cells and cell types generated, if any.

33. A method in accordance with claim 32, wherein the modulators comprise any culturing conditions that may modulate cellular
15 differentiation.

34. A method for screening for differentiation factors of cellular development comprising :

- (a) culturing the cells in serum free media at low cell density in the presence of the differentiation factor;
- 20 (b) allowing cells to differentiate;
- (c) detecting differentiation of the cells, if any.

35. A method of claim 34 for screening for modulators or differentiation factors of neural cell development.

36. A method for screening for differentiation factors of cellular
25 development comprising :

- 69 -

(a) culturing the cells of claims 25, 26, 27 or 28 in serum free media, in the presence of the differentiation factor.

(b) detecting any differentiation of the cells.

37. The method of claim 36, wherein the media further comprises FGF2.

5 38. A modulator or differentiation factor detected by the methods of claims 33-37.

39. The use of the modulator or differentiation factor of claim 38 for modulating cellular differentiation.

10 40. The use of the method of any of claims 1-11 for obtaining a homogenous uniform cell base.

41. The use of the method of claim 40 wherein the cell base is a neural cell base.

42. The use of the cells of claims 25, 26, 27 or 28 for supplying cells for transplantation.


15 43. The use of the cells of claim 25, 26, 27 or 28 for treatment of neurodegenerative disorders.

44. The use of the cells of claims 25, 26, 27 or 28 for the treatment of any disease or conditions resulting from cell loss or function in the neural system.

20 45. The use of the cell of claim 25, 26, 27 or 28 in gene therapy, wherein the cell is modified to express a gene of interest.




1/7

FIGURE 1



2/7


FIGURE 2

A**B**

	<u>ES</u>	<u>SC</u>	<u>+</u>
Emx2			
HoxB1			
Six3			
Otx1			
Brachyury			
GATA4			
HNF-4			
CK-17			


3/7

FIGURE 3



4/7



FIGURE 4



5/7


FIGURE 5
% Immunolabeled Cells**A**

Cell Line	50 cells/ul	10 cells/ul
Nestin		
β III-tubulin		
NeuN		
Oct-4		
R1	40.0 +/- 13.6	82.0 +/- 4.0
R1	13.3 +/- 2.3	51.0 +/- 8.9
R1	n.d.	29.0 +/- 2.5
R1	26.2 +/- 3.4	19.3 +/- 3.9

B


6/7

FIGURE 6



7/7

FIGURE 7



SEQUENCE LISTING

<110> Van Der Kooy, Derek

Tropepe, Vincent

<120> Primitive Neural Stem Cells and Method for Differentiation of Stem Cells to Neural Cells

<130> 2223-109

<150> US 60/236,394

<151> 2000-09-29

<160> 16

<170> PatentIn version 3.1

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Emx2: sense

<400> 1
gtcccagctt ttaaggctag a

21

<210> 2

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 2
cttttgcctt ttgaatttcg ttc

23

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> HoxB1: sense

<400> 3
ccggaccttc gactggatg

19

<210> 4

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 4
ggtcagaggc atctccagc

19

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Otx1: sense

<400> 5
tcacagctgg acgtgctcga

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 6
gcggcggttc ttgaacaaa

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Six3: sense

<400> 7
cgcgacctgt accacatcct

20

<210> 8

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 8
gccttggtca tcatacgta

20

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Brachyury: sense

<400> 9

agtatgaacc tcggattcac

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 10

ccggttggtta caagtctcag

20

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> GATA4: sense

<400> 11

agcctacatg gccgacgtgg

20

<210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 12

tcagccagga ccaggctgtt

20

<210> 13

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> HNF-4: sense

<400> 13

ccatggtgtt aaaggacgtg c

21

<210> 14

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 14

taggattcag atccccgagcc

20

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primers for GAPDH: sense

<400> 15

accacagtcc atgccatcac

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> antisense

<400> 16

tccaccaccc tgttgctgta

20

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 April 2002 (04.04.2002)

PCT

(10) International Publication Number
WO 02/026941 A3

(51) International Patent Classification:
A61P 25/28, A61K 48/00, C12N 5/06

C12N 5/08,

TROPEPE, Vincent [CA/US]; 56 Charlesgate East, Apt.
132, Boston, MA 02215 (US).

(21) International Application Number: PCT/CA01/01383

(74) Agent: BERESKIN & PARR; 40 King Street West, Box
401, 40th Floor, Toronto, Ontario M5H 3Y2 (CA).

(22) International Filing Date:

28 September 2001 (28.09.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(25) Filing Language:

English

(26) Publication Language:

English


(30) Priority Data:

60/236,394 29 September 2000 (29.09.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

[Continued on next page]

(54) Title: PRIMITIVE NEURAL STEM CELLS AND METHOD FOR DIFFERENTIATION OF STEM CELLS TO NEURAL CELLS



(57) Abstract: Described are a novel cell type in the neural lineage, and method of producing the same based on the degree of neural commitment and growth factor responsiveness in vitro and the potential to give rise to neural and non-neural progeny in vivo. The novel cell type of neural lineage and cells derived therefrom have a number of applications including applications regarding tissue engineering, transplantation and gene therapy and drug discovery. Also described are suggested uses of the method and cell type including isolating genes that positively and negatively regulate the transition from an ES cell to a neural cell and generally for studying ES cell models of mammalian neural development.

WO 02/026941 A3



IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
12 December 2002

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/01383

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N5/08 A61P25/28 A61K48/00 C12N5/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, SCISEARCH, BIOTECHNOLOGY ABS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	REYNOLDS B A ET AL: "A MULTIPOTENT EGF-RESPONSIVE STRIATAL EMBRYONIC PROGENITOR CELL PRODUCES NEURONS AND ASTROCYTES" JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 12, no. 11, 1 November 1992 (1992-11-01), pages 4565-4574, XP000574446 ISSN: 0270-6474 cited in the application page 4566, right-hand column, paragraph 2 -page 4567; figures 2,3 --- -/--	1-9, 12, 13, 19, 24-27, 30, 32-36, 40, 41

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

2 September 2002

Date of mailing of the international search report

09. 9. 02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ALCONADA RODRIG..., A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/01383

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TROPEPE V ET AL: "Autonomous neural cell fate specification in mouse embryonic stem cells." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 25, no. 1-2, 1999, page 527 XP001077071 29th Annual Meeting of the Society for Neuroscience, Part 1; Miami Beach, Florida, USA; October 23-28, 1999 ISSN: 0190-5295 cited in the application	1, 3-17, 19-31, 36-41
Y	abstract	18, 32-37
X	WO 99 32606 A (BRUESTLE OLIVER) 1 July 1999 (1999-07-01) page 20, line 19-26 page 23, line 13 -page 24, line 18 examples 2-4	24-26, 28, 30, 31, 36, 42-45
Y	WO 99 01553 A (GENETICS INST ; UNIV CALIFORNIA (US)) 14 January 1999 (1999-01-14) page 13, line 15-24	18
Y	WO 99 01159 A (UNIV UTAH RES FOUND) 14 January 1999 (1999-01-14) page 56, line 3-26; claim 44	32-37
P, X	TROPEPE VINCENT ET AL: "Direct neural fate specification from embryonic stem cells: A primitive mammalian neural stem cell stage acquired through a default mechanism." NEURON, vol. 30, no. 1, April 2001 (2001-04), pages 65-78, XP002202327 ISSN: 0896-6273 cited in the application the whole document	1-37, 40, 41
A	NAGY A ET AL: "Derivation of completely cell culture-derived mice from early-passage embryonic stem cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 90, no. 18, 15 September 1993 (1993-09-15), pages 8424-8428, XP002182191 ISSN: 0027-8424	

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 01/01383

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>OTERO J J ET AL: "Cell-cell contact regulates commitment by cultured embryonic stem cells."</p> <p>SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, 2001, page 341 XP002202328</p> <p>31st Annual Meeting of the Society for Neuroscience; San Diego, California, USA; November 10-15, 2001</p> <p>ISSN: 0190-5295</p> <p>abstract</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA 01/01383

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 38 and 39 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-23, 27, 32-35,
40 and 41 (complete) and 38-39 (partially)

A method for differentiating embryonic stem cells to cells with markers characteristic of neural cells comprising culturing an embryonic stem cell in serum free media at low density and allowing said cells to differentiate; the use of said method for analyzing the role of genes in the regulation of neural fate specification; methods for screening for modulators and differentiation factors by culturing the cells in the presence of the factor to be tested; use of the method for obtaining an homogenous uniform cell base.

2. Claims: 24-26, 28-31, 36,
37 and 42-45 (complete) and 38-39 (partially)

Cells expressing one or more neural precursor cell marker and one or more neural-cell specific mRNA molecules, a cell produced by the method of invention 1; a method for producing a cell type comprising allowing the neural precursor cells to differentiate; a method for the identification of factors that influence the differentiation of the neural precursor cells into a predetermined cell type; the use of said cells for transplantation, for the treatment of neurodegenerative disorders and to modify them to express the gene of interest.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 38 and 39 (partially)

Present claims 38 and 39 relate to a product and the use thereof, wherein the product is defined by reference to a desirable characteristic or property, namely, that they can be detected by the methods of claims 33-37.

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the products that influence the differentiation of embryonic stem cells plated at low density into neural-progenitor cells, namely, EGF, FGF2 and LIF (see examples 1-3), and noggin and mCcr-1 (see example 4).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 01/01383

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9932606	A	01-07-1999	DE 19756864 C1	29-04-1999
			AU 2510699 A	12-07-1999
			CA 2315538 A1	01-07-1999
			WO 9932606 A2	01-07-1999
			EP 1040185 A2	04-10-2000
			JP 2001526884 T	25-12-2001
WO 9901553	A	14-01-1999	US 5935852 A	10-08-1999
			AU 749031 B2	20-06-2002
			AU 7814098 A	25-01-1999
			EP 1012278 A1	28-06-2000
			JP 2002511762 T	16-04-2002
			WO 9901553 A1	14-01-1999
WO 9901159	A	14-01-1999	AU 8382398 A	25-01-1999
			EP 1011732 A1	28-06-2000
			JP 2002515071 T	21-05-2002
			WO 9901159 A1	14-01-1999
			ZA 9805887 A	26-04-1999

THIS PAGE BLANK (USPTO)